Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up


D. Planchard1, S. Popat2, K. Kerr3, S. Novello4, E. F. Smit5, C. Faiivre-Finn6, T. S. Mok7, M. Reck8, P. E. Van Schiff9, M. D. Hellmann10 & S. Peters11, on behalf of the ESMO Guidelines Committee*

1Department of Medical Oncology, Thoracic Group, Gustave-Roussy Villejuif, France; 2Royal Marsden Hospital, London; 3Aberdeen Royal Infirmary, Aberdeen University Medical School, Aberdeen, UK; 4Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy; 5Thoracic Oncology Service, Netherlands Cancer Institute, Amsterdam, The Netherlands; 6Division of Cancer Sciences, University of Manchester, Manchester, UK; 7Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; 8LungenClinic Airway Research Center North (ARCN), German Center for Lung Research, Grosshansdorf, Germany; 9Department of Thoracic and Vascular Surgery, Antwerp University Hospital and Antwerp University, Antwerp, Belgium; 10Weill Cornell Medical College, New York, USA; 11Medical Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, CH-6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org


Incidence and epidemiology

Primary lung cancer remains the most common malignancy after non-melanocytic skin cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1]. In 2012, lung cancer was the most frequently diagnosed cancer in males with an estimated 1.2 million incident cases worldwide. Among females, lung cancer was the leading cause of cancer death in more developed countries and the second leading cause of cancer death in less developed countries [1]. The highest incidence is found in Central/Eastern Europe and Asia with age-standardised incidence rates of 53.5 and 50.4 per 100 000, respectively. European projections for 2017 indicate a 10.7% drop in 5 years with an incidence of 33.3/100 000 in males and a rise of 5.1% and an incidence of 14.6/100 000 in females [2]. Contrary to the United States, the death rate in females is increasing in Europe [3]. The number of lung cancer-related deaths in Europe for 2017 is estimated to represent the leading cause of cancer deaths in both genders, accounting for 24% in males and 15% in females, respectively [2].

Non-small cell lung cancer (NSCLC) accounts for 80–90% of lung cancers, while small cell lung cancer (SCLC) has been decreasing in frequency in many countries over the past two decades [4]. During the last 25 years, the distribution of histological types of NSCLC has changed: in the United States, squamous cell carcinoma (SCC), formerly the predominant histotype, decreased, while adenocarcinoma has increased in both genders. In Europe, similar trends have occurred in men, while in women, both SCC and adenocarcinoma are still increasing [5].

The World Health Organization (WHO) estimates that lung cancer is the cause of 1.59 million deaths globally per year, with 71% of them caused by smoking. Tobacco smoking remains the main cause of lung cancer and the geographical and temporal patterns of the disease largely reflect tobacco consumption during the previous decades. Both smoking prevention and smoking cessation can lead to a reduction in a large fraction of lung cancers [6]. In countries with active tobacco control measures, the incidence of lung cancer has begun to decline in men and is reaching a plateau for women [1, 7–9]. Several other factors have been described as lung cancer risk factors, including exposure to asbestos, arsenic, radon and non-tobacco-related polycyclic aromatic hydrocarbons. Hypotheses about indoor air pollution (e.g. coal-fuelled stoves and cooking fumes) are made for the relatively high burden of non-smoking-related lung cancer in women in some countries [10]. There is evidence that lung cancer rates are higher in cities than in rural settings but many confounding factors other than outdoor air pollution may be responsible for this pattern.

About 500 000 deaths annually are attributed to lung cancer in lifetime never-smokers [1]. Absence of any history of tobacco smoking characterises 19% of female compared with 9% of male lung carcinoma in the United States [11, 12]. An increase in the proportion of NSCLC in never-smokers has been observed, especially in Asian countries [13]. These new epidemiological data have resulted in ‘non-smoking-associated lung cancer’ being considered a distinct disease entity, where specific molecular and genetic tumour characteristics have been identified [14].
Use of non-cigarette tobacco products such as cigars and pipes has been increasing. A pooled analysis highlighted the increased risk, particularly for lung and head and neck cancers, in smokers (former and current) of cigars and pipes [15].

Familial risk of lung cancer has been reported in several registry-based studies after careful adjustment for smoking [16]. A recent study estimated the heritability of lung cancer at 18% but many of the genetic components remain unidentified. Genome-wide association studies (GWAS) have identified lung cancer susceptibility loci including CHRNA3, CHRNA5, TERT, BRCAn2, CHECK2 and the human leukocyte antigen (HLA) region [17–19]. Another trial, including data from 29 266 cases and 56 450 controls from European descent, found 18 susceptibility loci reaching genome-wide significance, among which 10 were previously unknown. Interestingly, while four of the latter were associated with overall lung cancer risk, six were associated with lung adenocarcinoma only [20].

Diagnosis and pathology/molecular biology

Diagnosis

Changes in the therapeutic scenario in the last 15 years have emphasised the need for a multidisciplinary approach in lung cancer. Data show that high-volume centres and multidisciplinary teams are more efficient at managing patients with lung cancer than low-volume or non-multidisciplinary centres, by providing more complete staging, better adherence to guidelines and increased survival [21, 22]. Multidisciplinary tumour boards influence providers’ initial plans in 26%–40% of cases [23]. The absolute need to reach a proper and precise morphological and biological definition often requires challenging tissue sampling, with most treatment decisions depending on the information obtained from the specimen collected at diagnosis.

Bronchoscopy is a technique ideally suited to large, central lesions and offers the advantage of minimal morbidity. Bronchoscopy can be used for bronchial washing, brushing, bronchial and transbronchial biopsy, with a diagnostic yield of 65%–88% [24–26]. By combining direct bronchoscopic airway visualisation with ultrasound-guided biopsy of the lesion, endobronchial ultrasound (EBUS) provides a diagnostic yield of 75%–85% in large, centrally located lesions [27, 28]. Fibre optic bronchoscopy allows for the evaluation of regional lymph nodes by EBUS and/or endoscopic ultrasound (EUS). EBUS-guided transbronchial needle aspiration (TBNA) is less invasive and at least as accurate as mediastinoscopy [29]. Several studies have shown that cytological specimens obtained by EBUS-TBNA are suitable for molecular testing for epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homologue (KRAS) and anaplastic lymphoma kinase (ALK) status [30–33]; however, collection of samples suitable for broader molecular diagnostic testing should be encouraged.

In case of peripheral lesions, transthoracic percutaneous fine needle aspiration and/or core biopsy, under imaging guidance (typically computed tomography (CT)) is proposed [34]. Needle biopsy is associated with a diagnostic accuracy of > 88% yield, a sensitivity of 90% and a false-negative rate of 22% [25, 35–38]. The most significant disadvantage of transthoracic needle biopsy is a procedural risk of pneumothorax, ranging from 17% to 50% [37, 38].

In the presence of a pleural effusion, thoracentesis could represent both a diagnostic tool and a palliative treatment. If fluid cytology examination is negative, image-guided pleural biopsy or surgical thoracoscopy should be carried out. More invasive, surgical approaches [mediastinoscopy, mediastinotomy, thoracoscopy, video-assisted thoracoscopic surgery (VATS), secondary lesion resection etc.] in the diagnostic workup are considered when the previously described techniques cannot allow for an accurate diagnosis.

Pathology/molecular biology

Histological diagnosis

Histological diagnosis of NSCLC is crucial to many treatment decisions and should be as exact and detailed as the samples and available technology allow. Diagnosis should be based upon the criteria laid out in the WHO classification [39]. This classification details the complete diagnostic approach for surgically resected tumours but, importantly, also provides guidance for assessing small biopsy and cytology samples where complete morphological criteria for specific diagnosis may not be met [39–41].

Most patients with NSCLC present with advanced stage unresectable disease, therefore all treatment-determining diagnoses must be made on small biopsy and/or cytology-type samples. Sampling may be carried out of the primary tumour or any accessible metastases, taken under direct vision or more usually with image-guided assistance, which greatly increases the diagnostic yield (hit rate). Sampling metastatic disease may facilitate staging, as well as diagnosis. These diagnostic samples frequently have limited tumour material and must therefore be handled accordingly; ensuring processing is suitable for all likely diagnostic procedures and that material is used sparingly at each step, since many diagnostic tests may be required [42].

Immunohistochemistry (IHC) has become a key technique in primary diagnosis as well as in predictive biomarker assessment. In those cases of NSCLC where specific subtyping is not possible by morphology alone, a limited panel of IHC is recommended to determine the subtype [39, 40]. Thyroid transcription factor 1 (TTF1) positivity is associated with probable diagnosis of adenocarcinoma, p40 positivity with probable diagnosis of SCC; if neither are positive the diagnosis remains NSCLC—not otherwise specified (NOS). IHC staining should be used to reduce the NSCLC-NOS rate to < 10% of cases diagnosed [IV, A]. Pathologists are urged to conserve tissue at every stage of diagnosis, to use only
two tissue sections for IHC NSCLC subtyping and to avoid excessive IHC investigation, which may not be clinically relevant.

**Molecular diagnostics**

After morphological diagnosis, the next consideration is therapy-predictive biomarker testing. This practice will be driven by the availability of treatments and will vary widely between different geopolitical health systems [43–45]. Contemporary practice has now evolved into two testing streams, one for the detection of targetable, usually additive, oncogenic alterations and the other for immuno-oncology therapy biomarker testing. A personalised medicine synopsis table is shown in Table 1.

Several molecular drivers for oncogene addiction represent strong predictive biomarkers and excellent therapeutic targets. They are generally mutually exclusive of each other [43–45]. These tumours are much more common in never- (never smoked or who smoked < 100 cigarettes in lifetime), long-time ex- (>10 years) or light-smokers (< 15 pack-years) but can also be found in patients who smoke. The vast majority of oncogene-addicted lung cancers are adenocarcinomas. Patients, in general, tend to be younger, while female gender and East Asian ethnicity particularly enriches for EGFR-mutant tumours. Nonetheless, guidelines suggest that all patients with advanced, possible, probable or definite, adenocarcinoma should be tested for oncogenic drivers [43–46]. Molecular testing is not recommended in SCC, except in those rare circumstances when SCC is found in a never-, long-time ex- or light-smoker (< 15 pack-years) [IV, A]. Testing for EGFR mutations and rearrangements involving the ALK and ROS1 genes are now considered mandatory in most European countries. In many oncology services, BRAF V600E mutations as testing is also mandated as first-line BRAF/MEK inhibitors are more widely approved. NTRK1 (neurotrophic tyrosine receptor kinase 1) has emerged as a target with approved treatments in many European countries. HER2 (human epidermal growth factor receptor 2) and MET exon 14 mutations and fusion genes involving RET are evolving targets/biomarkers [43–46].

EGFR tyrosine kinase inhibitors (TKIs) are established effective therapies in patients who have activating and sensitising mutations in exons 19–21 of EGFR [47]. Prevalence is around 10%–20% of a Caucasian population with adenocarcinoma but much higher in Asian populations. Around 90% of the most common mutations comprise deletions in exon 19 and the L858R substitution mutation in exon 21. Any testing approach must cover these mutations [I, A]; however, complete coverage to include exons 18–21 is recommended [II, B]. The T790M exon 20 substitution mutation is only rarely found in EGFR TKI-naive disease using standard techniques but is the most frequent cause of resistance to first- and second-generation EGFR TKIs (50%–60% of cases). Cases of patients carrying germline T790M mutation have also been reported [48]. Further studies to better understand the prevalence, familial penetrance and lifetime lung cancer risk in germline T790M-mutant patients are warranted. Implications of this mutation in TKI-naive disease are unclear, but the availability of TKIs effective against T790M-mutant recurrent disease makes T790M testing on disease relapse mandatory [I, A]. Cell-free DNA (cfDNA) blood testing is an acceptable approach to detect T790M at relapse but lacks sensitivity, so all patients with a negative blood test still require tissue biopsy [II, A] [49]. Tissue biopsy may also be more effective in identifying other resistance mechanisms which may require alternative treatment (SCLC transformation, MET amplification, HER2 alterations etc.).

Fusion genes involving ALK and a number of partners (most commonly EML4) account for around 2%–5% of the same population that is routinely tested for EGFR mutations [50]. ALK-driven adenocarcinoma is very sensitive to several ALK TKIs. Early trials validated break-apart fluorescent in situ hybridisation (FISH) as the test to identify ALK gene rearrangement but the close association between a positive FISH test and modestly elevated ALK protein in tumour cells (TCs) allows ALK IHC to be used, either to select cases for confirmatory FISH testing or as the primary therapy-determining test [50, 51]. ALK IHC must reliably detect low levels of ALK protein and be validated against alternative tests to detect ALK fusion genes, especially if ALK IHC is used as the therapy-determining assay, without confirmation by FISH [II, A]. Emerging data demonstrate that the presence of the ALK protein (positive IHC staining) is associated with treatment response [I, A] [52, 53]. IHC has been accepted as an equivalent alternative to FISH for ALK testing [54]. Testing for ALK rearrangement should be systematically carried out in advanced non-squamous NSCLC [I, A]. ALK mutations are emerging as important resistance mechanisms to ALK TKIs and ALK mutation testing may soon become a routine test at relapse as newer-generation ALK TKIs show differential efficacy against different ALK mutations [55].

ROS1 fusion genes are yet another additive oncogenic driver that occurs in ~1%–4% of the same testing population. Like ALK, ROS1 has several potential fusion gene partners. Crizotinib, a TKI effective against ALK and MET, and entrectinib (see below) are also approved by the European Medicines Agency (EMA) for use in ROS1-rearranged adenocarcinomas. FISH has been the standard approach to detecting ROS1 rearrangements. IHC may be used in a manner similar to ALK testing, to identify candidate tumours for confirmatory FISH testing. The sensitivity of this approach is high, using currently available IHC, but specificity of IHC is low [IV, C]. FISH or other testing is required to confirm the diagnosis; IHC is currently not recommended as the primary treatment determining test [IV, A] [45, 46, 50]. Testing for ROS1 rearrangement should be systematically carried out in advanced non-squamous NSCLC [III, A]. Next-generation sequencing (NGS) of tumour-derived RNA is merging as an alternative molecular test for screening or confirming the presence of fusion genes.

BRAF mutation testing is now required in many countries after the approval of BRAF and MEK inhibitors for BRAF V600-mutant NSCLC. Any method is valid provided that it is adequately sensitive for the samples used and has been appropriately quality-assured, both within the laboratory and through external quality assurance. The V600E mutation is the most common of the BRAF V600 family and, overall, these BRAF mutations are found in ~2% of cases. BRAF V600
mutations appear mutually exclusive to EGFR and KRAS mutations, ALK and ROS1 rearrangements and are similarly much more common in adenocarcinoma. BRAF V600 mutation status should be systematically analysed in advanced non-squamous NSCLC for the prescription of BRAF/MEK inhibitors [II, A].

NTRK gene rearrangements are the latest family of oncogenic driver alterations to receive regulatory approval in Europe as a target for kinase inhibitor therapy (see later). In many health systems, this approval is tissue-agnostic; there is no caveat related to the type of tumour in which the NTRK fusion is found. This is something of a logistic challenge for laboratories as testing potentially all solid malignant tumours is currently outwith the capabilities of most. NTRK fusions are found relatively frequently is a small group of very rare paediatric and adult tumours but are generally exceptionally rare in common adult solid tumours with prevalence in lung adenocarcinoma probably around 0.2% [55a, 55b, 55c]. There are alternative testing approaches which are used, depending of laboratory resources and probability of finding a positive, and these are reflected in the ESMO guidelines and other publications [55a, 55d]. Both NGS and immunohistochemistry are valid screening options. A positive NTRK IHC test requires confirmation of the rearrangement by a validated molecular method such as FISH or NGS, while the ESMO guidelines also introduce the concept of biologically validating any fusion gene suggested by NGS, using IHC; similar to the emerging paradigm in ALK testing, where the protein appears to be important for therapy response.

For many laboratories, testing for EGFR and BRAF mutations and ALK and ROS1 rearrangements involves individual standalone tests. Multiplex, massively parallel, so-called NGS of various sorts is rapidly being adopted as the standard approach to screening adenocarcinomas for oncogenic targets [III, A] [45, 49, 50, 56]. Platform-specific, commercially available panels can cover genes of interest and provide a comprehensive, multiplex test for mutations and, in some cases, fusion genes. This multiplex approach is especially valuable, and more efficient, when the number of targets increases. Consequently, with emerging targets in advanced NSCLC such as HER2 and KRAS mutations and MET exon14 skipping mutations, such a multiplex approach is increasingly likely to be necessary. It is also worth noting that MET exon14 skipping mutations may be better identified using RNA as opposed to DNA sequencing, akin to our approach with fusion genes [56a, 56b]. NGS will not address biomarkers that require testing at the protein level (requires IHC) and the question of whether NGS-detected fusion genes require an orthogonal test (IHC, FISH) for confirmation remains open. Whatever testing modality is used, it is mandatory that adequate internal validation and quality control measures are in place and that laboratories participate in, and perform adequately, external quality assurance schemes for each biomarker test [III, A].

The approval of the anti-programmed cell death protein 1 (PD-1) agent pembrolizumab as a standard-of-care first-line treatment in selected patients has made programmed death-ligand (PD-L1) IHC a mandatory test in all patients with advanced NSCLC. Although the PD-L1 IHC 22C3 assay was the only test validated in clinical trials of pembrolizumab, extensive technical comparison studies suggest that trial-validated commercial kit assays based on the 28-8 and SP263 PD-L1 IHC clones may be alternative tests [III, A] [57–61]. If laboratories use, by choice or force of circumstances, a non-trial-validated PD-L1 IHC test, i.e. a laboratory developed test (LDT), there is a high risk that the assay may fail quality assurance and a very careful, extensive validation is essential before clinical use [IV, A] [35, 36]. There is a relationship between the extent of PD-L1 expression on TCs, or in some trials in tumour infiltrating immune cells (ICs), and the probability of clinical benefit from numerous anti-PD-1 or PD-L1 agents, in first- and second-line monotherapy [57]. For pembrolizumab, the mandatory treatment threshold is a tumour proportion score (TPS, presence of PD-L1 signal on tumour cell membranes) ≥ 50% in first line and ≥ 1% in second line [62, 63]. PD-L1 expression testing is recommended for all patients with newly diagnosed advanced NSCLC [I, A]. For nivolumab and atezolizumab in second line, PD-L1 testing is not required for drug prescription. PD-L1 IHC is an approved biomarker test for immunotherapeutics in NSCLC but it is not a perfect biomarker; less than half of biomarker-selected patients benefit from treatment and some responses may be encountered in ‘biomarker-negative’ cohorts. The selective power of PD-L1 IHC is much less obvious in the context of immuno-oncology combination therapy, but PD-L1 IHC testing status is still a valuable parameter to assist in nuanced decisions over the best immunotherapy approach for individual patients.

Much work is underway to identify alternative, or more likely, additional biomarkers to enrich patient populations for response. Various measures of tumour mutational burden (TMB) are being explored and TMB has been validated prospectively in a unique prospective clinical trial to-date [64]. An international effort is ongoing to define a consensus on how TMB should be measured [65–67]. Assessment of tumour inflammation is also of interest, but again, various approaches are being pursued, including histological assessment of immune cell infiltrates and mRNA-based expression signatures of immune-related genes. More data are required before any of these new approaches can be routinely incorporated into NSCLC biomarker testing.

Blood monitoring

The ability to detect oncogenic driver genomic alterations, or factors associated with disease resistance to treatment in peripheral blood, opens the way to disease monitoring in a way that would not be practically feasible were repeat testing solely based upon tumour biopsy testing. In practice, and with current knowledge, this is more likely to involve the use of cfDNA rather than circulating tumour cells (CTCs). The vast majority of existing data and experience concern EGFR mutation testing in blood [68], although there is expanding use of cfDNA testing upfront in advanced NSCLC patients in some centres [68a]. Currently, much EGFR plasma testing is based upon highly sensitive allele-specific polymerase chain reaction (ASPCR). Plasma genotyping may be considered before undergoing a tumour biopsy to detect the T790M mutation. However, if the plasma testing is negative for T790M, the tissue biopsy is strongly recommended to determine T790M status because of the risks of false-negative plasma results [III, A]. NGS techniques can be used; as more biomarkers are identified and validated, more NGS-based gene panels would be available.
Notwithstanding the issues regarding sensitivity of blood testing, potentially clinically valuable information may be derived from serial blood testing during treatment. For example, the disappearance from the blood of the primary sensitising EGFR mutation is associated with clinical and radiological evidence of response to EGFR TKIs and is a good prognostic indicator [IV, C].

After maximum response to EGFR TKI therapy and disappearance of the mutation from the plasma, the reappearance of the primary sensitising mutation, with or without detection of the T790M resistance mutation, may be an indicator of ‘biochemical’ disease relapse. This occurrence may predate radiological relapse, which, in turn, may predate clinical/symptomatic disease relapse. Currently, such findings are essentially exploratory since there is no consensus as to when and how any clinical intervention should be managed. There is no doubt, however, that this kind of molecular monitoring could, in the future, offer benefit to patients in a number of different personalised treatment scenarios.

TMB was evaluated in patient tissue as well as blood samples in different trials. Unique assays and cut-offs are not yet defined but preliminary data from the POPLAR and OAK trials found TMB in blood is associated with improved atezolizumab clinical benefit in patients with NSCLC [69]. Exploratory data suggesting blood TMB (bTMB) as a predictive biomarker for atezolizumab as well as durvalumab/tremelimumab activity front-line have recently been presented [70, 70a]. bTMB measured from ctDNA allows for rapid, less invasive testing and may be more representative of the heterogeneity of metastatic lesions. Two prospective trials in the first-line setting are exploring the same biomarker [NCT03178552; NCT02542293].

Staging and risk assessment

A complete medical history with comorbidities, weight loss, performance status (PS) and physical examination must be recorded. An exhaustive smoking habit assessment has to be included, indicating type, quantity and timing.

Laboratory

Standard tests including routine haematology, renal and hepatic function and bone biochemistry tests are required. The routine use of serum markers, such as carcinoembryonic antigen (CEA), is not recommended [IV, B] [71].

The neutrophil to lymphocyte ratio (NLR) is a widely available blood-based data point, validated in numerous oncological settings as a potential prognostic marker. NLR has been considered as a potential dynamic marker but further prospective validations are needed [IV, C] [72, 73].

Radiology

Baseline imaging

A contrast-enhanced CT scan of the chest and upper abdomen including complete assessment of liver, kidneys and adrenal glands should be carried out. Imaging of the central nervous system (CNS) is most relevant in those patients with neurological symptoms or signs [IV, A]; however, if available, imaging of the CNS with magnetic resonance imaging (MRI, preferably with gadolinium enhancement) or CT of the brain with iodinated contrast should be carried out at diagnosis [IV, B]. MRI is more sensitive than CT scan [III, B] [74].

Leptomeningeal disease (LMD) is a deadly complication of solid tumours and has a poor prognosis. Adenocarcinomas are the most common tumours to metastasise to the leptomeninges. In case of clinical suspicion, LMD diagnostic imaging should include the brain and the spinal cord, as LMD can impact the entire neuraxis. If metastatic disease has been determined by CT scan of the chest and upper abdomen or by brain imaging, other imaging is only necessary if it has an impact on treatment strategy. If bone metastases are clinically suspected, bone imaging is required [IV, B]. Bone scan or positron emission tomography (PET), ideally coupled with CT, can be used for detection of bone metastasis [IV, B]. PET-CT is the most sensitive modality in detecting bone metastasis [II, B] [75]. Fluorodeoxyglucose (FDG)-PET or PET-CT has higher sensitivity and specificity than bone scintigraphy [76]. FDG-PET-CT scan also has high sensitivity for the evaluation of solitary pulmonary nodules, intra-thoracic pathological lymph nodes and distant metastatic disease [77]. However, the low sensitivity of this exam in small lesions, in lesions close to FDG-avid structures (overprojection) or in lesions that move extensively, such as those just above the diaphragm, should be considered. MRI may complement or improve the diagnostic staging accuracy of FDG-PET-CT imaging, particularly in assessing local chest wall, vascular or vertebra invasion and is also effective for identification of nodal and distant metastatic disease. NSCLC is staged according to the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) system (8th edition) and is grouped into the stage categories shown in Tables 2 and 3 [78, 79].

In the presence of a solitary metastatic lesion on imaging studies, including pleural and pericardial effusion, efforts should be made to obtain a cytological or histological confirmation of stage IV disease [IV, A].

Response evaluation

Response evaluation is recommended after 2–3 cycles of chemotherapy (ChT) or immunotherapy, using the same initial radiographic investigation that demonstrated tumour lesions [IV, B]. The same procedure and timing (every 6–9
weeks) should be applied for the response evaluation in patients treated with targeted therapies and/or immunotherapy [IV, B]. Follow-up with PET is not routinely recommended, due to its high sensitivity and relatively low specificity [IV, C].

Measurement of lesions should follow Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 [IV, A] [80]. The adequacy of RECIST in evaluating response to EGFR or ALK TKIs in respective genetically driven NSCLC is still debatable even if this remains the standard method of evaluation for these patients [IV, B]. In these two subgroups of patients (and in other actionable oncogene alterations), treatment beyond RECIST progression is a common approach, pursuing clinical benefit more than morphological response. This approach differs from what was carried out historically with cytotoxic agents. The conventional radiological response criteria are unable to describe pseudoprogression (PsPD) and can result in underestimation of the therapeutic benefit of immune checkpoint blockade. Several radiological criteria have been developed specifically for immunotherapy, to better define the tumour response in this context. Two-dimensional immune-related response criteria (irRC) were proposed in 2009 and modified in 2013 with the immune-related RECIST (irRECIST) [81, 82]. More recently, the RECIST working group published a proposition of new criteria called immune-RECIST (iRECIST), to standardise response assessment among immunotherapy clinical trials [83]. A subsequent adaption of iRECIST designed to better capture cancer immunotherapy responses has been published: immune-modified RECIST (imRECIST) [84]. More data are needed to compare the RECIST, iRECIST, imRECIST and irRECIST to quantify the differences in outcome estimation before using of them in clinical practice. Nonconventional responses and PsPD are very rarely observed in NSCLC, ranging generally under 5% of all cases, and RECIST v1.1 should still be used in routine practice [IV, B] [85–88].

Management of advanced/metastatic NSCLC

The treatment strategy (Figures 1–7) should take into account factors such as histology, molecular pathology, age, PS, comorbidities and the patient’s preferences. Treatment decisions should ideally be discussed within a multidisciplinary tumour board who can evaluate and change management plans, including recommending additional investigations and changes in treatment modality [89]. Systemic therapy should be offered to all stage IV patients with PS 0–2 [I, A].

In any stage of NSCLC, smoking cessation should be highly encouraged: it can improve outcome and smoking may interact with systemic therapy [II, A]. For example, smoking reduces erlotinib bioavailability [90, 91]. Given the established relationship between smoking and lung cancer, patients who have smoked may feel stigmatised or guilty after diagnosis and more pessimistic about their illness and likely outcomes, all of which may have adverse implications for health-related quality of life (QoL) [92].

For these reasons, healthcare professionals should give clear advice about the adverse implications of continued smoking and include smoking cessation programmes in the therapeutic algorithm.

First-line treatment of EGFR- and ALK-negative NSCLC, PD-L1 ≥ 50%

Lung cancers were previously considered poorly immunogenic, with minimal benefit seen in historical studies of cytokine modulation or vaccines. However, the recent development of immune checkpoint inhibitors has upended this belief and provided proof of principle that immunotherapy can play an important role in the treatment of patients with lung cancers.

The phase III KEYNOTE-024 study has established the role for pembrolizumab as first-line treatment in patients with untreated, advanced NSCLC and tumour characterised by PD-L1 expression ≥ 50% [62], in absence of EGFR mutation or ALK translocations. In KEYNOTE-024, 1934 patients were screened to identify 500 patients (30%) with tumour PD-L1 expression ≥ 50%. Of these patients, 305 patients were randomised to receive 200 mg pembrolizumab every 3 weeks (up to 2 years) or 4–6 cycles of standard platinum-doublet ChT. All efficacy measures favoured pembrolizumab, including objective response rate (ORR 45% versus 28%), progression-free survival [PFS, hazard ratio (HR) 0.5, 95% confidence interval (CI) 0.37–0.68, P<0.001] and overall survival (OS, HR 0.6, 95% CI 0.41–0.89, P=0.005). Safety and QoL also favoured pembrolizumab [93]. Continued follow-up has further emphasised the effectiveness of pembrolizumab, with median OS (mOS) doubled in those who received pembrolizumab compared with ChT (30 versus 14 months) [94, 94a].

Pembrolizumab is considered a standard first-line option for patients with advanced NSCLC and PD-L1 expression ≥ 50% who do not otherwise have contraindications to use of immunotherapy (such as severe autoimmune disease or organ transplantation) [I, A; European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) v1.1 score: 5].

KEYNOTE-042 and CheckMate 026 examined a lower threshold for PD-L1 [66, 95, 95a]. Recent results from KEYNOTE-042, a phase III study of patients with PD-L1 ≥ 1% who were randomised to either pembrolizumab or ChT, demonstrated improved OS in patients treated with pembrolizumab at three thresholds of PD-L1: ≥ 50%, ≥ 20% and ≥ 1%. The HR for OS was 0.69, 0.77 and 0.81, respectively. Overall, the preponderance of the OS benefit was driven by patients with ≥ 50%, while no significant increase was seen in those patients with 1%–49% PD-L1 expression (HR 0.92, 95% CI 0.77–1.11).

In CheckMate 026, patients with untreated, advanced NSCLC and PD-L1 ≥ 1% (analysis based on 5% threshold) were randomised to nivolumab or platinum-doublet ChT [66]. There were no improvements in any efficacy metrics. However, an exploratory retrospective and unplanned analysis examined the impact of TMB on benefit of nivolumab. A
total of 312 patients (58% of randomised patients) had sufficient tissue for whole exome sequencing. In those patients with the highest tertile of TMB (> 243 missense non-synonymous somatic mutations per sample), ORR (47% versus 28% with ChT) and PFS (HR 0.62, 95% CI 0.38–1.0) favoured those who received nivolumab. Meanwhile, among patients with low or medium TMB, ORR was numerically better in those who received ChT (33% versus 23% with nivolumab).

Overall, these results confirm the benefit of pembrolizumab in the first-line setting seen in KEYNOTE-024, restricted to patients with high PD-L1 expression (≥ 50%).

In the phase III IMPower110 study patients were randomised 1:1 to receive atezolizumab, 1200 mg every 3 weeks (arm A), or 4 or 6 cycles of platinum-based ChT (arm B) [95b]. In an interim survival analysis, atezolizumab monotherapy improved OS compared with platinum-based ChT as a first-line treatment of patients with wild-type NSCLC who had ≥ 50% expression of PD-L1 on TC3 or ≥ 10% expression on tumour-infiltrating IC3. Atezolizumab monotherapy improved OS by 7.1 months compared with ChT alone (median OS was 20.2 versus 13.1 months; HR 0.595, 95% CI 0.398–0.890, P=0.0106). Median PFS was 8.1 months (95% CI 6.8–11.0) in the atezolizumab arm and 5.0 months (95% CI 4.2–5.7) in the ChT arm (HR 0.63; 95% CI 0.45–0.88, P=0.007); the confirmed ORR was 38.3% versus 28.6%, respectively. The OS testing boundary was not crossed in the TC2/3 or IC2/3 wild-type population (PD-L1 expression of 5% or greater by TCs or ICs), so OS was not formally tested in this population as well as in the TC1/2/3 and IC1/2/3 populations (PD-L1 expression of 1% or greater by TC or IC). Atezolizumab represents a promising first-line treatment option in patients with PD-L1-high (following the specific definition of TC3 or IC3 per trial design) NSCLC [I; A; not EMA-approved], with the formal caution of a subgroup analysis compared with trial design and ITT using only TC > 50% [I, B].

### First-line treatment of EGFR- and ALK-negative NSCLC disease, regardless of PD-L1 status

Recently, results of the phase III trials KEYNOTE-189, IMPower150, IMPower132 and IMPower131 have brought new options for the therapeutic choices in first line of non-squamous NSCLC and trials KEYNOTE-407 and IMPower131 for patients with squamous NSCLC.

In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0–1, without sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and cisplatin or carboplatin plus either 200 mg of pembrolizumab or placebo every 3 weeks for 4 cycles, followed by pembrolizumab or placebo for up to a total of 35 cycles plus pemetrexed maintenance therapy [96]. The mOS in the pembrolizumab/ChT arm was 22.0 months (95% CI 19.5–25.2) versus 10.7 months (95% CI 8.7–13.6) in the ChT arm (HR 0.56, 95% CI 0.45–0.70, P<0.00001). The PFS also favoured the pembrolizumab/ChT combination (HR 0.48, 95% CI 0.40–0.58, P<0.00001) [96a]. The OS benefit of pembrolizumab/ChT was observed in all PD-L1 tumour subgroups. Based on the results from KEYNOTE-189, pembrolizumab in combination with pemetrexed and a platinum-based ChT should be considered a standard option in metastatic non-squamous NSCLC [I; A; ESMO-MCBS v1.1 score: 4] [96b].

In IMPower150, the addition of atezolizumab to bevacizumab plus ChT significantly improved PFS and OS among patients with metastatic non-squamous NSCLC, regardless of PD-L1 expression [97, 97a]. The PFS was longer in the atezolizumab/bevacizumab/ChT arm compared with bevacizumab/ChT in patients without EGFR mutation or ALK rearrangement [median PFS (mPFS) 8.3 versus 6.8 months; HR 0.62, 95% CI 0.52–0.74, P<0.001]. In this patient group, survival was longer in the atezolizumab/bevacizumab/ChT arm compared with bevacizumab/ChT (mOS 19.8 versus 14.9 months; HR 0.76, 95% CI 0.63–0.93).

Results from IMPower150 place the combination of atezolizumab and bevacizumab with carboplatin and paclitaxel as a therapeutic option in patients with PS 0–1 with metastatic non-squamous NSCLC, in absence of contraindications to use of immunotherapy [I, A, ESMO-MCBS v1.1 score: 3]. Of note, this is the only trial to-date also including patients with EGFR or ALK genetic alterations. In EGFR-mutant patients, median OS was not estimable (NE, 95% CI 17.0–NE) with atezolizumab plus bevacizumab plus carboplatin plus paclitaxel and 18.7 months (95% CI 13.4–NE) with bevacizumab plus carboplatin plus paclitaxel (HR 0.61, 95% CI 0.29–1.28). Improved OS with atezolizumab plus bevacizumab plus carboplatin plus paclitaxel was observed in patients with sensitising EGFR mutations, defined as exon 19 deletions or L858R mutations (HR 0.31, 95% CI 0.11–0.83) [97a]. This association defines a treatment opportunity in EGFR-positive NSCLC patients after targeted therapies have been exploited [III, A; ESMO-MCBS v1.1 score: 3].

Recently, the combination of carboplatin or cisplatin with pemetrexed and atezolizumab followed by maintenance pemetrexed and atezolizumab has been shown, in the context of the IMPower132 trial, to be superior to the ChT doublet followed by maintenance pemetrexed. An improvement in mPFS from 5.2 to 7.6 months was observed (HR 0.6, 95% CI 0.49–0.72, P=0.0001) while OS was not statistically significantly increased at the time of analysis with mOS of 18.1 versus 13.6 months (HR 0.81, 95% CI 0.64–1.03; P=0.0797), with final OS still awaited [I, B; not EMA-approved] [98].

IMPower130 is an additional multicentre, randomised, open-label, phase 3 study randomising stage IV NSCC patients: 2:1 to receive atezolizumab (1200 mg every 3 weeks) and carboplatin/albunin-bound paclitaxel (nab-P) (4–6 cycles), followed by maintenance atezolizumab to ChT alone (maintenance with pemetrexed switch or best supportive care). This trial showed a significant improvement in OS (18.6 versus 13.9 months; HR 0.79, 95% CI 0.64–0.98; P=0.033) and PFS (7.0 versus 5.5 months, HR 0.64, 95% CI 0.54–0.77, P<0.0001) with atezolizumab plus ChT versus ChT as first-line treatment, offering a new standard treatment opportunity in this subgroup of patients [98a] [I, A; ESMO-MCBS v1.1 score: 3].
KEYNOTE-407 is a randomised, placebo-controlled study of patients with metastatic squamous NSCLC [99]. Patients were randomised 1:1 to receive carboplatin and paclitaxel every 3 weeks or nab-P weekly plus pembrolizumab or placebo for 4 cycles, followed by pembrolizumab or placebo for a total of 35 treatments. The combination of ChT plus pembrolizumab was associated with improved ORR (58.4% versus 35.0%; P=0.0004) and improved OS (HR 0.64, mOS 15.9 versus 11.3 months; P=0.0008). The benefit in OS was seen across PD-L1 expression strata (TPS < 1% HR 0.61, TPS 1–49% HR 0.57, TPS ≥50% HR 0.64). No new safety concerns were observed. Addition of pembrolizumab to ChT maintained or improved HRQoL measurements relative to baseline and improved HRQoL versus ChT alone at weeks 9 and 18. Results from KEYNOTE-407 place the combination of pembrolizumab plus carboplatin and paclitaxel or nab-P as a standard choice in patients with metastatic squamous NSCLC [i, A; ESMO-MCBS v1.1 score: 4] [99a].

Atezolizumab was studied in patients with metastatic squamous NSCLC in the IMpower131 study. Patients were randomised to atezolizumab/carboplatin/paclitaxel, atezolizumab/carboplatin/nab-P or carboplatin/nab-P [100]. Atezolizumab/carboplatin/nab-P had improved PFS compared with carboplatin/nab-P (HR 0.715, P=0.0001), but no improvement in final OS was seen (mOS 14.2 versus 13.5 months) [100a]. In the PD-L1-high subgroup, median OS was 23.4 versus 10.2 months, respectively. While atezolizumab with carboplatin and nab-P improves PFS in patients with metastatic squamous NSCLC, it was not shown to improve OS, favouring today the combination reported in KEYNOTE-407 [I, B; not EMA-approved].

One key area of uncertainty is among PD-L1 TPS ≥50%, as none of these trials provide a direct comparison between ChT plus checkpoint inhibitors versus pembrolizumab monotherapy. However, cross-trial comparison between trials suggest similar OS outcomes among PD-L1 ≥50%, with very different toxicity profiles, suggesting that pembrolizumab monotherapy may remain a reasonable choice for patients with PD-L1 ≥50% [101].

TMB has shown encouraging results as a predictive biomarker in retrospective studies in NSCLC and SCLC. The first prespecified analysis of TMB as a biomarker was reported in the phase III trial CheckMate 227, evaluating nivolumab plus ipilimumab versus ChT in first-line NSCLC [64]. The TMB cut-off of 10 mutations per megabase (Mb) using the FoundationOne CDx assay was determined based on data from CheckMate 568 based on receiver operating characteristic (ROC) curves and clinical impact analysis [102]. Patients with newly diagnosed advanced NSCLC were randomised based on PD-L1 expression. Those who had PD-L1 TPS ≥1% received nivolumab/ipilimumab, nivolumab monotherapy or ChT; and those with a PD-L1 < 1% received nivolumab/ipilimumab, nivolumab/ChT or ChT. Two co-primary endpoints have been defined and both reported as positive: PFS in high TMB for nivolumab/ipilimumab versus ChT and OS for nivolumab/ipilimumab versus ChT in positive PD-L1 patients. In patients with high TMB (>10 mutations/ Mb, 44% of assessable patients), nivolumab/ipilimumab was associated with longer PFS than ChT (HR 0.58, 97.5% CI 0.41–0.81, P<0.001), and more than tripling of 1-year PFS (42.6% versus 13.2%). The PFS benefit with nivolumab/ipilimumab was seen irrespective of PD-L1, wherein the HR similarly favoured nivolumab plus ipilimumab in patients with a PD-L1 TPS ≥1% and those <1% (HR 0.62 and HR 0.48, respectively). A similar benefit was seen in both squamous and non-squamous histologies (squamous HR 0.63; non-squamous HR 0.55). Of importance, there was no difference in PFS among patients with <10 mutations/Mb (HR 1.07, 95% CI 0.84–1.35). In contrast, TMB could not identify patients with improved survival on nivolumab/ipilimumab, with TMB harbouring a prognostic impact in this patients population.

The dual co-primary endpoints of the CheckMate 227 study was OS in patients whose tumours expressed PD-L1 (assessed in patients enrolled in part 1). OS was improved versus ChT independent of their PD-L1 status or TMB [102a]. Median OS among the patients with PD-L1 expression >1% (the primary endpoint) was improved with nivolumab plus ipilimumab versus ChT (17.1 versus 14.9 months; HR 0.79). Among the patients with PD-L1 expression <1%, median OS was also improved with nivolumab plus ipilimumab (17.2 versus 12.2 months, HR 0.64). Rates of grade 3 or 4 toxicity among all patients were similar with nivolumab plus ipilimumab or ChT alone (32.8% and 36%, respectively). While the role of TMB remains to be defined, nivolumab/ipilimumab improves OS above ChT in PD-L1 positive patients [i, A] as well as in the negative subgroup [ii, A]. There is no approval to-date of this combination in Europe.

For now, nivolumab plus ipilimumab represents an optional treatment regimen for patients with NSCLC [i, A; not EMA-approved]. Important questions remain regarding the role of immunotherapy combinations versus PD-1 monotherapy in PD-L1 TPS ≥50% and how TMB may inform the optimal use of PD-L1 plus ChT versus immunotherapy alone combinations in NSCLC. The MYSTIC trial enrolled 1118 patients with metastatic NSCLC who were randomly allocated to durvalumab alone, durvalumab plus tremelimumab or ChT. The primary endpoints were OS for durvalumab versus ChT, and OS and PFS for durvalumab plus tremelimumab versus ChT in patients with 25% or greater PD-L1 expression in TCS. Durvalumab alone or with tremelimumab did not improve OS or PFS compared to ChT (OS: 16.3 versus 12.9 months, HR 0.76 and 11.9 versus 12.9 months, HR 0.85; PFS: 4.7 versus 5.4 months, HR 0.87 and 3.9 versus 5.4 months, HR 1.05, respectively). Exploratory analysis demonstrated that high blood TMB (≥20 mutations/Mb) was associated with longer OS in durvalumab and tremelimumab versus ChT (21.9 versus 10 months, HR 0.49) [79a]. Additional prospective clinical data, including a randomised phase III trial (NEPTUNE) and evaluation of long-term benefit of these new strategies are awaited. Physicians and patients will need to conduct individualised discussions regarding benefit and risks of available therapies over time.

CheckMate 9LA is a phase 3 randomised study evaluating nivolumab plus ipilimumab and 2 cycles of ChT versus ChT in first-line stage IV/recurrent NSCLC. At a preplanned interim analysis (minimum follow-up of 8.1 months), mOS was significantly prolonged with nivolumab plus ipilimumab and ChT (14.1 months) versus ChT (10.7 months) (HR 0.69, 95.71% CI 0.55–0.87, P=0.0006) [i, A] [102b]. Subgroup analysis indicated that the combination regimen gave rise to
longer mOS than ChT alone for both squamous (14.5 versus 9.1 months, HR 0.62) and non-squamous histology (17.0 versus 11.9 months, HR 0.69), and for both PD-L1-positive (≥ 1%, HR 0.64) and PD-L1-negative tumours (< 1%, HR 0.62). Grade 3–4 treatment-related adverse events (AEs) occurred in 47% of patients given nivolumab plus ipilimumab and ChT versus 38% of controls, with 16% and 5% of such events leading to discontinuation of any treatment, respectively. There is no approval to-date of this combination in Europe.

Overall, the results from the KEYNOTE-024, KEYNOTE-042, IMpower110, CheckMate 227, MYSTIC, CheckMate 9LA, IMpower150, KEYNOTE-189, IMpower132, IMpower130, KEYNOTE-407 and IMpower131 trials suggest that introducing immunotherapy as a standard approach for most patients with newly diagnosed NSCLC.

First-line treatment of NSCLC without actionable oncogenic driver, with contraindications to use of immunotherapy

ChT with platinum doublets should be considered in all stage IV NSCLC patients without an actionable oncogenic driver, without major comorbidities and PS 0–2 [I, A]. Benefits of ChT versus best supportive care (BSC), namely a 23% reduction of risk of death, a 1-year survival gain of 9% and a 1.5-month absolute increase in median survival and improved QoL, were observed irrespective of age, sex, histology and PS in two meta-analyses [103–105]. The survival benefit of two-agent over one-agent ChT regimens was reported in a meta-analysis in 2004; no survival benefit was observed for three-agent over two-agent regimens [106]. Based on a 2006 meta-analysis, revealing a statistically significant reduction (equal to 22%) in the risk of death at 1 year for platinum over non-platinum combinations, without induction of unacceptable increase in toxicity, platinum-based doublets are recommended in all patients with no contraindications to platinum compounds [I, A] [107]. Neither a large individual trial nor a meta-analysis found an OS benefit of 6 versus fewer cycles of first-line platinum-based doublets, although a longer PFS coupled with significantly higher toxicity was reported in patients receiving 6 cycles [108, 109]. Therefore, 4 cycles of platinum-based doublets followed by less toxic maintenance monotherapy [I, A], or 4 cycles in patients not suitable for maintenance monotherapy [I, A], up to a maximum of 6 cycles [IV, B], is currently recommended.

Several platinum-based regimes with third-generation cytotoxics (paclitaxel, gemcitabine, docetaxel, vinorelbine) have shown comparable efficacy [110, 111]. The expected toxicity profile should contribute to the selection of the ChT regimen, taking into account that:

- A recent Cochrane review including 10 trials with 3973 patients available for meta-analysis could not demonstrate any difference between carboplatin-based and cisplatin-based ChT in OS. Cisplatin had higher ORRs in an overall analysis but trials using paclitaxel or gemcitabine plus a platinum agent in both arms had equivalent response. Cisplatin caused more nausea or vomiting and carboplatin caused more thrombocytopenia and neurotoxicity, while no difference in the incidence of grade 3-4 anaemia, neutropenia, alopecia or renal toxicity was observed [112].
- The carboplatin/nab-P regimen has been shown in a large phase III trial to have a significantly higher ORR compared with solvent-based paclitaxel/carboplatin (sb-PC), and less neurotoxicity [I, B] [113]. The benefits were observed in both SCC and non-SCC (NSCC), with a larger impact on response in SCC. For this reason, the carboplatin/nab-P regimen could be considered a chemotherapeutic option in advanced NSCLC patients, particularly in patients with greater risk of neurotoxicity, pre-existing hypersensitivity to paclitaxel or contraindications for standard paclitaxel premedication [I, B].

First-line treatment of SCC

Most individual trials and meta-analyses evaluating ChT options in the first-line treatment of advanced NSCLC did not report any differential efficacy in patients with SCC [104]. Therefore, platinum-based doublets with the addition of a third-generation cytotoxic agent (gemcitabine, vinorelbine, taxanes) are recommended in advanced SCC patients without major comorbidities and PS 0–2 [I, A] (Figure 1).

Necitumumab, an immunoglobulin G1 (IgG1) monoclonal antibody against EGFR, did not demonstrate a significant impact in first-line treatment of metastatic NSCC when added to cisplatin/pemetrexed [114]. However, outcomes were different when necitumumab was combined with different ChT regimens in SCC. In the SQUIRE trial, the addition of necitumumab to cisplatin/gemcitabine produced a significant OS improvement (11.5 versus 9.9 months, HR 0.84, 95% CI 0.74–0.96, P=0.01) and PFS improvement, with a 1-year survival equal to 48% in the experimental arm versus 43% in the control arm [115]. In a retrospective analysis, the group of patients expressing EGFR (assessed by IHC) showed an improvement in OS and PFS [mOS 11.7 months versus 10.0 months, HR 0.79, 95% CI 0.69–0.92, P=0.002; mPFS 5.7 versus 5.5 months, HR 0.84, 95% CI 0.72–0.92, P=0.018] [116]. Based on these results, due to the limited clinical improvement, the addition of necitumumab to cisplatin and gemcitabine has not been adopted as a standard in Europe for advanced SCC and its use should be carefully evaluated [I, C; ESMO-MCBS v1.1 score: 1].

First-line treatment of NSCC

Any platinum-based doublets with a third-generation agent including gemcitabine, vinorelbine or taxanes can be used in NSCC (Figure 2). The incorporation of pemetrexed and bevacizumab into individual treatment schedules should be considered, based on the following:

- Pemetrexed-based combination ChT represents a therapeutic option, based on the results of a recent meta-analysis that showed a slight but significant survival benefit compared with gemcitabine- or docetaxel-based
combinations and of a pre-planned subgroup analysis of a large randomised phase III trial [II, A] [117, 118]. Pemetrexed use should be restricted to NSCC in any line of treatment in advanced disease [II, A] [119, 120].

- The survival benefit of carboplatin in combination with pemetrexed has been investigated in a meta-analysis (exploratory subgroup analysis); survival benefit for pemetrexed plus platinum held true for cisplatin-containing regimens but not for carboplatin-based regimens; however, results from prospective randomised studies investigating this question are not yet available [117]. The combination of carboplatin with pemetrexed can be an option in patients with a contraindication to cisplatin [II, B].

- Findings of two randomised clinical trials revealed that bevacizumab improves OS when combined with paclitaxel/carboplatin regimens in patients with NSCC and PS 0–1 and, therefore, may be offered in the absence of contraindications in eligible patients with advanced NSCC (bevacizumab should be given until progression) [I, A] [121, 122]. A randomised phase III trial evaluating gemcitabine/cisplatin combination with or without bevacizumab demonstrated an ORR and modest PFS advantage, but no OS benefit [123].

Two meta-analyses showed a consistent significant improvement in ORR, PFS and OS for the combination of bevacizumab and platinum-based ChT, compared with platinum-based ChT alone in eligible patients with NSCC [124, 125]. Bevacizumab might therefore be considered with platinum-based regimens beyond paclitaxel/carboplatin in the absence of contraindications [II, B]. Treatment with bevacizumab has also shown encouraging efficacy and acceptable safety in patients with NSCC and asymptomatic, untreated brain metastases [126].

**Maintenance**

Decision-making about maintenance therapy must take into account histology, residual toxicity after first-line ChT, response to platinum doublet, PS and patient preference. Several trials have investigated the role of maintenance treatment in patients with good PS (0–1) either as ‘continuation maintenance’ or as ‘switch maintenance’. ‘Continuation maintenance’ and ‘switch maintenance’ therapies refer to the maintained use of an agent included in first-line treatment or the introduction of a new agent after 4 cycles of platinum-based ChT, respectively. One randomised phase III switch maintenance trial has reported improvements in PFS and OS with pemetrexed [120] and erlotinib [127] versus placebo, following 4 cycles of platinum-based ChT. In the case of pemetrexed, this benefit was seen only in patients with NSCC [I, B]. Furthermore, the phase III IUNO study (maintenance erlotinib) failed to meet its primary endpoint of OS (HR 1.02, 95% CI 0.85–1.22, P=0.85) [128]. Maintenance treatment with erlotinib is only recommended for NSCC patients with an EGFR-sensitising mutation [III, B]. Randomised trials investigating continuation maintenance have shown an improvement in PFS and OS. A large phase III randomised trial of continuation maintenance with pemetrexed versus placebo after 4 induction cycles of cisplatin plus pemetrexed ChT demonstrated a PFS and OS improvement in patients with a PS 0–1, confirmed at long-term follow-up [129, 130]. mOS was 13.9 months (95% CI 12.8–16.0) with pemetrexed and 11.0 months (95% CI 10.0–12.5) with placebo, with 1- and 2-year survival rates significantly longer for patients given pemetrexed (58% and 32%, respectively) than for those given placebo (45% and 21%). Another phase III study comparing maintenance bevacizumab, with or without pemetrexed, after first-line induction with bevacizumab, cisplatin and pemetrexed showed a benefit in PFS for the pemetrexed/bevacizumab combination but no improvement in OS [131], although a trend towards improved OS was seen when analysing 58% of events of 253 patients randomised for this study [132]. In the PointBreak trial, which compared carboplatin/paclitaxel/bevacizumab followed by bevacizumab with carboplatin/pemetrexed/bevacizumab followed by pemetrexed/bevacizumab, OS was comparable in both arms (12.6 versus 13.4 months; HR 1.00, 95% CI 0.86–1.16, P=0.949) [133]. In a phase III trial, it was also shown that continuation maintenance with gemcitabine significantly reduces disease progression (mPFS 3.8 versus 1.9 months, HR 0.56, 95% CI 0.44–0.72) with a non-significant OS improvement in patients with advanced NSCLC treated with 4 cycles of cisplatin/gemcitabine as first-line ChT [I, C] [134]. Continuing pemetrexed following completion of 4 cycles of first-line cisplatin/pemetrexed ChT is, therefore, recommended in patients with NSCC, in the absence of progression after first-line ChT and upon recovery from toxicities from the previous treatment [I, A]. Of note, three studies, one employing bevacizumab and the other two using monoclonal antibodies against EGFR (cetuximab or nectumab) administered concomitantly to ChT and further continued as monotherapy until disease progression, have demonstrated survival benefits; however, the specific role of the maintenance phase cannot be appreciated in this context [115, 121, 135].

**PS 2 and beyond**

ChT prolongs survival and improves QoL in NSCLC patients with PS 2 when compared with BSC [I, A] [136, 137]. A recently published meta-analysis of randomised trials comparing the efficacy and safety of platinum-based doublets versus single-agent regimens in the first-line therapy of PS 2 patients revealed platinum-based regimens to be superior in terms of ORR and survival despite an increase in toxicities (mainly haematological) [138]. The superiority of carboplatin-based combinations over monotherapy in PS 2 patients has been identified within two large phase III trials [137, 139], with an acceptable toxicity profile. Therefore, platinum-based (preferably carboplatin) doublets should be considered in eligible PS 2 patients [I, A]. Single-agent ChT with gemcitabine, vinorelbine, docetaxel [I, B] or pemetrexed (restricted to NSCC) [II, B] is an alternative treatment option [139, 140].

All phase III studies with immunotherapies reported until today excluded patients with PS ≥ 2. Reported in abstract form only, CheckMate 153 included 108 patients with advanced NSCLC and PS 2 treated with single-agent nivolumab [141]. mOS was 3.9 months and 1-year survival 23%, being lower than observed in patients with PS 0–1. Toxicities
associated with treatment were comparable between PS 0–1 and PS 2 patients. Interestingly, an improvement in patient-reported outcomes was observed for non-squamous NSCLC patients in the context of this trial. In a European-based safety phase II trial (CheckMate 171), among 809 patients enrolled, 98 PS 2 patients were treated with nivolumab; the safety was comparable to the overall population with an mOS of 5.4 months [142]. In conclusion, insufficient data are available to-date on the use of checkpoint inhibitors for these patients, but this treatment option can be considered [III, B].

Poor PS (3–4) patients should be offered BSC in the absence of documented sensitising alterations such as EGFR mutations, ALK or ROS1 rearrangements or BRAF V600 mutation [III, B].

Elderly patients

In the early 2000s, based on several phase III trials, single-agent ChT over BSC was established as the standard of care for first-line therapy of advanced NSCLC patients aged > 70 years [140, 143]. A recent systematic review identified platinum-based combination ChT as the preferred option for patients > 70 years of age with PS 0–2 and adequate organ function [144]. Here, data from 13 randomised controlled trials (RCTs) with 1705 patients > 70 years of age showed that the addition of platinum agents resulted in improvement in OS (HR 0.76, 95% CI 0.69–0.85), PFS (HR 0.76, 95% CI 0.61–0.93) and ORR (RR 1.57, 95% CI 1.32–1.85) compared with non-platinum-containing therapy. Carboplatin was associated with an OS benefit (HR 0.67, 95% CI 0.59–0.78) whereas cisplatin was not (HR 0.91, 95% CI 0.77–1.08). Treatment with platinum-based combinations comes at the expense of more treatment-related morbidity, mainly anaemia, thrombocytopenia, emesis, diarrhoea and peripheral neuropathy: this should be weighed against the expected survival benefit. It is noteworthy that those RCTs that included formal QoL analysis found no difference in QoL between treatment with platinum-based combinations or single agents in this population [137, 145]. Nevertheless, concerns about treatment-related toxicity in the elderly population has led to the study of comprehensive geriatric assessment (CGA) as a selection tool for treatment with either platinum-containing regimens, single-agent therapy or BSC based on patient’s fitness or frailty. The sole prospective randomised trial reported failed to demonstrate an improvement in time to treatment failure and OS for advanced NSCLC patients > 70 years when treatment (carboplatin doublet, single-agent ChT or BSC) was allocated based on CGA alone or a combination of PS and age. Also, the incidence of grade 3–4 toxicities was not different between the two arms in this study [46]. Carboplatin-based doublet ChT is recommended in eligible elderly patients with PS 0–2 and with adequate organ function [I, A]. The addition of a checkpoint inhibitor to this regimen has not been formally and specifically evaluated in elderly patients aged > 65 years when treatment (carboplatin doublet, single-agent ChT or BSC) was allocated based on CGA alone or a combination of PS and age. Also, the incidence of grade 3–4 toxicities was not different between the two arms in this study [46]. Carboplatin-based doublet ChT is recommended in eligible elderly patients with PS 0–2 and with adequate organ function [I, A]. The addition of a checkpoint inhibitor to this regimen has not been formally and specifically evaluated in elderly patients > 65 years, but might be preferred, in absence of any signal of toxicity excess from immunotherapy in this population. In PS 2, independent of age, insufficient data are available to-date on the use of checkpoint inhibitors for these patients, but ChT and immunotherapy combination shall however be considered [III, B]. For those patients not eligible for doublet ChT, single-agent ChT remains the standard of care [I, B].

Evidence is accumulating for immune checkpoint inhibitors in elderly patients with advanced NSCLC. Although no studies dedicated to elderly patients were reported yet, it can be inferred that ORRs and survival are not different between patients ≤ 65 years and those > 65, based on subgroup analysis of the randomised second-line trials [63, 147–150]. Of note, no differences in toxicities were observed [149]. In KEYNOTE-024, comparing first-line pembrolizumab with combination ChT in advanced NSCLC patients whose tumours expressed PD-L1 > 50%, half the randomised patients were > 65 years of age. In the subgroup analysis, the beneficial effect of pembrolizumab was not different between patients aged ≤ 65 years and > 65 years of age (HR 0.61 versus 0.45) [62]. Likewise, in CheckMate 028, comparing nivolumab with combination ChT in unselected first-line advanced NSCLC patients, there was no difference in survival outcomes between patients treated with nivolumab aged ≤ 65 years and those > 65 years [66]. Immunotherapy should therefore be considered according to standard recommendations in elderly patients [III, A].

Second-line treatment of NSCLC without actionable oncogenic driver

In the few years since benefit was shown with PD-1 blockade in lung cancers, three PD-1 or PD-L1 therapies have been approved by the United States Food and Drug Administration (FDA) and the EMA in the second-line setting. The three approved therapies in the immunotherapy-naive, second-line setting include nivolumab, pembrolizumab and atezolizumab. Each has been approved on the basis of phase III studies demonstrating improved OS in comparison with docetaxel. Results are summarised below. Overall, there are no major differences in terms of efficacy or safety among these three therapies to inform a single optimal choice, and no comparative studies have been conducted. There are two key distinctions between the three approved therapies, which can affect choice and use:

1. PD-L1 expression: nivolumab and atezolizumab are approved in patients with PD-L1 treated, advanced NSCLC irrespective of PD-L1 expression, whereas pembrolizumab is approved only in patients with PD-L1 ≥ 1%
2. Schedule of administration: atezolizumab and pembrolizumab are approved to be given once every three weeks, while nivolumab is given once every two weeks based on current EMA approval. Of note, the FDA has recently approved a 4-weekly schedule for nivolumab.

Overall, any of these three therapies represents reasonable standard therapy for most patients with advanced, previously treated, PD-L1-naive NSCLC. Treatment of patients with a history of autoimmune disease should be considered only with caution and after discussion of risks/benefits. Because of the risk of graft rejection, anti-PD-1/PD-L1 agents should be avoided in patients with solid organ transplantation. For reference, we summarise the key data from the relevant phase III studies here:
Nivolumab: two phase III studies, CheckMate 017 and CheckMate 057, have established the effectiveness of nivolumab in the second-line setting [147, 148]. In CheckMate 017, 272 patients with squamous NSCLC were randomised to nivolumab or docetaxel. OS was significantly improved in those who received nivolumab (HR 0.59, 95% CI 0.44–0.79, P<0.001). In CheckMate 057, 582 patients with non-squamous NSCLC were randomised to nivolumab or docetaxel. OS was significantly improved with nivolumab (HR 0.73, 95% CI 0.59–0.89, P=0.002). In a recent update of these studies, 2-year OS favoured nivolumab in both squamous (29% versus 16% with docetaxel) [I, A; ESMO-MCBS v1.1 score: 5] and non-squamous NSCLC (23% versus 8%) [I, A; ESMO-MCBS v1.1 score: 5]. Tolerability also favoured nivolumab, with 10% of patients experiencing grade 3–4 treatment-related AE's compared with 55% with docetaxel.

Pembrolizumab: The KEYNOTE-010 trial randomised 1034 patients with previously treated NSCLC with PD-L1 expression on at least 1% of TCGs to receive pembrolizumab (tested at two doses, 2 mg/kg or 10 mg/kg, each given every three weeks) or docetaxel 75 mg/m^2 every 3 weeks [63, 151]. OS was significantly longer for pembrolizumab versus docetaxel (2 mg/kg; HR 0.71, 95% CI 0.58–0.88, P<0.001; 10 mg/kg; HR 0.61, 95% CI 0.49–0.75, P<0.001), with a recently reported 2-year OS rate of 14.5% versus 30.1% (2 mg/kg group) [I, A; ESMO-MCBS v1.1 score: 5]. Grade 3–5 treatment-related AE's were less common with pembrolizumab than with docetaxel (13%–16% versus 35%). There was no significant difference in the efficacy or safety of pembrolizumab at 2 or 10 mg/kg.

Atezolizumab: The OAK trial [149, 149a] evaluated 850 patients with advanced NSCLC previously treated with one or two prior lines of ChT, who were randomised to atezolizumab or docetaxel. OS was significantly improved with atezolizumab (HR 0.73, 95% CI 0.62–0.87, P<0.001). Tolerability was also better with atezolizumab, with 15% of patients experiencing a grade 3–4 treatment-related toxicity compared with 43% of those treated with docetaxel [I, A; ESMO-MCBS v1.1 score: 5].

There is a general trend across each of the phase III studies in second-line (nivolumab, pembrolizumab and atezolizumab versus docetaxel) for enriched efficacy of anti-PD-1/PD-L1 agents in patients with higher PD-L1 expression compared with those with no/less PD-L1 expression. However, unselected patients may still have improved survival and tolerability with anti-PD-1/PD-L1 agents compared with docetaxel [I, A].

Therefore, anti-PD-1/PD-L1 agents are the treatment of choice for most patients with advanced, previously treated, PD-L1-naive NSCLC, irrespective of PD-L1 expression [I, A].

Combination ChT regimens failed to show any OS benefit over single-agent treatments in second line. Single agents improve disease-related symptoms and OS. Docetaxel has shown improved efficacy compared with BSC in randomised trials with a significant improvement in OS in the TAX 320 trial for those patients who received docetaxel at a dose of 75mg/m^2 every 3 weeks [152, 153]. Similar efficacy, but more favourable tolerability for the weekly schedule, could be confirmed in randomised trials comparing 3-weekly to weekly schedules of docetaxel [I, B] [154, 155].

Pemetrexed demonstrated comparable OS to docetaxel in a randomised phase III trial but had a more favourable toxicity profile, with lower rates of neutropenia, alopecia and gastrointestinal events [156]. A retrospective analysis confirmed a predictive impact of histology with an improved efficacy of pembrolizumab compared with docetaxel in patients with non-squamous NSCLC (mOS 9.0 versus 8.3 months; HR 0.78, 95% CI 0.61–1.0, P=0.004) [119].

While registration trials of pemetrexed and docetaxel did not limit therapy to a set number of treatment cycles, second-line treatment duration should be individualised. Treatment may be prolonged if disease is controlled and toxicity acceptable [II, B].

Docetaxel and pemetrexed (for NSCC only) are confirmed treatment options in second-line ChT, with comparable efficacy [I, B], taking into account that immunotherapy is now the current standard second-line systemic therapy and that these agents have not been formally assessed after checkpoint inhibitors.

In several trials, the combination of antiangiogenic agents with ChT has been investigated in patients with pretreated advanced NSCLC. In the REVEL trial, ramucirumab, a vascular endothelial growth factor receptor 2 (VEGFR2) antibody, in combination with docetaxel, showed a superior OS (mOS 10.5 versus 9.1 months, HR 0.86, 95% CI 0.75–0.98, P=0.032) and PFS (mPFS 4.5 versus 3 months, P<0.0001) compared with docetaxel and placebo regardless of histology [I, B; ESMO-MCBS v1.1 score: 1] [157]. The main AE's associated with ramucirumab consisted of myelotoxicity, oedema and mucositis. The efficacy of this combination was also preserved in the poor prognosis group of patients who did not show any response to first-line ChT [157, 158]. Nintedanib, an oral angiokinase inhibitor, improved PFS in combination with docetaxel compared with ChT alone in the LUME-1 trial (mPFS 3.4 versus 2.7 months, HR 0.79, 95% CI 0.68–0.92, P=0.0019) [159]. A significant prolongation of OS was observed in the group of patients with adenocarcinoma histology (mOS 12.6 versus 10.3 months; HR 0.82, 95% CI 0.7–0.99, P=0.0359). Gastrointestinal events and transient elevation of liver enzymes were the most frequent AE's associated with nintedanib. However, the QoL analyses did not show any impact on QoL measurements for this combination. Again, improved efficacy was seen in the poor prognosis group of patients with nonresponder or fast progressing tumours [159, 160].

The efficacy of the combination of antiangiogenic agents and ChT was confirmed in the ULTIMATE trial, which showed prolongation of PFS for the combination of weekly paclitaxel and bi-weekly bevacizumab compared with docetaxel (mPFS 5.4 versus 3.9 months, HR 0.62, 95% CI 0.44–0.86, P=0.005) with no difference in OS [161]. The combination of ramucirumab and docetaxel represents a treatment option for patients with NSCLC progressing after previous ChT or immunotherapy, with PS 0–2 [I, B; ESMO-MCBS v1.1 score: 1]. The combination of nintedanib and docetaxel represents a treatment option for patients with adenocarcinoma progressing after previous ChT or immunotherapy [II, B]. Combination of paclitaxel and bevacizumab is another treatment option [I, C; not EMA-approved].
Erlotinib represents a potential second-/third-line treatment option, in particular for patients not suitable for immunotherapy or second-line ChT in unknown EGFR status or EGFR wild-type (WT) tumours [II, C]. Erlotinib has shown superiority in OS compared with BSC in pretreated patients not eligible for further ChT (mOS 6.7 versus 4.7 months, HR 0.7, 95% CI 0.58–0.85, P<0.001) [162]. In two additional trials, comparable efficacy of erlotinib and ChT has been reported for patients with refractory NSCLC (progression during first-line platinum-based ChT) or in second-/third-line therapy [163, 164].

In recent years, a growing number of reports revealed an inferior efficacy of EGFR TKIs in pretreated patients with EGFR WT tumours compared with ChT [165]. In a meta-analysis summarising the results of 6 randomised trials with 900 patients, PFS for EGFR TKI was significantly inferior to ChT in the group of patients with EGFR WT tumours (HR 1.37, 95% CI 1.20–1.56, P=0.00001). However, these results did not translate into an OS difference (HR 1.02, 95% CI 0.87–1.20, P=0.81) [166]. An additional analysis of the Biomarkers France study reported a significant improvement in PFS or OS for second-line ChT compared with second-line EGFR TKI in 1278 patients with pretreated NSCLC (PFS 4.3 versus 2.83 months, HR 0.66, 95% CI 0.57–0.77; OS 8.39 versus 4.99 months, HR 0.7, 95% CI 0.59–0.83, P<0.0001) [167].

In patients with advanced SCC, afatinib was investigated versus erlotinib in the LUX-Lung 8 trial. PFS and OS were improved in favour of afatinib (PFS 2.4 versus 1.9 months, HR 0.82, 95% CI 0.68–1.00, P=0.041; OS 7.9 versus 6.8 months, HR 0.81, 95% CI 0.69–0.95, P=0.0077) [168]. Afatinib was associated with improved prespecified disease-related symptoms and health-related QoL [169].

Aftinib could be a therapeutic option in patients with advanced SCC with PS 0–2 unfit for ChT or immunotherapy, progressing on or after ChT with unknown EGFR status or EGFR WT [I, C; ESMO-MCBS v1.1 score: 2]. In conclusion, patients clinically or radiologically progressing after first-line therapy with PS 0–2 should be offered second-line therapy, irrespective of administration of maintenance treatment [I, A]. So far, no prospective trials have determined the best second-line therapy following failure of first-line treatment with pembrolizumab; however, according to the first-line trial results, the preferred recommendation would be a platinum-based ChT, as discussed above [V, B] [62].

**Treatment of EGFR-mutated NSCLC**

**First-line treatment**

*EGFR* mutation is the best established oncogenic target for management of advanced stage NSCLC [170, 171]. The predictive power of *EGFR* mutation is confirmed in multiple randomised phase III studies comparing first- (erlotinib or gefitinib) or second-generation (afatinib) EGFR TKIs with standard platinum-based ChT [I, A] [172–177]. The benefit of improvement in ORR and PFS is consistent across all age groups, genders, smoking status and PS. Notably, none of the above studies have shown any benefit in OS for an EGFR TKI over platinum-based ChT, likely due to the high level of crossover. EGFR TKIs represent the standard of care as first-line treatment for advanced *EGFR*-mutated NSCLC [I, A] (Figures 3 and 4). Patients with PS 3–4 may also be offered an EGFR TKI as they are likely to receive a similar clinical benefit as patients with good PS [III, A] [178]. Patients who have benefited from EGFR TKI treatment may continue to receive the same therapy beyond initial radiological progression as long as they are clinically stable [II, A] [179]. Patients with localised distant progression and ongoing systemic control, continuation of treatment with EGFR TKI in combination with local treatment of progressing metastatic sites may be considered [III, B]. Continuous use of EGFR TKI in combination with ChT is not recommended as it was not associated with PFS improvement [I, A] and showed a detrimental effect on OS [II, B] [180].

The choice between first- and second-generation EGFR TKIs was investigated in two randomised studies. LUX-Lung 7 is a randomised phase IIb study that compares afatinib with gefitinib [181]. The study reported similar tumour ORR and a modest difference in PFS (mPFS 11.0 versus 10.9 months; HR 0.73, 95% CI 0.57–0.95, P=0.0165). The other co-primary endpoint for this study was OS and was not statistically different (mOS 27.9 versus 24.5 months; HR 0.86, 95% CI 0.66–1.12, P=0.258) [182]. More specifically, there was no difference in OS in patients with *EGFR* exon 19 mutation, which is contrary to the earlier claim of benefit in this subgroup from the pooled analysis of LUX-Lung 3 and LUX-Lung 6 studies [183].

ARCHER 1050 is a randomised phase III study that compares dacomitinib with gefitinib in stage IV *EGFR*-mutated lung cancer patients without CNS metastasis [184, 185]. The study reported significant improvement in PFS (mPFS 14.7 versus 9.2 months; HR 0.59, 95% CI 0.47–0.74, P=0.00001). The update mOS (median follow-up of 47.9 months) was 34.1 months with dacomitinib versus 27.0 months with gefitinib (HR 0.74, 95% CI 0.59–0.94, P=0.0155) [185a]. The OS probabilities at 30 months were 56.2% and 46.3% with dacomitinib and gefitinib, respectively. Both afatinib and dacomitinib are associated with higher incidence of grade 3 skin and gastrointestinal toxicity and a significant proportion of patients require dose reduction. Erlotinib, gefitinib and afatinib are recommended as first-line therapy in patients with advanced NSCLC who have active sensitising *EGFR* mutations, regardless of their PS [I, A]. Dacomitinib represents another treatment option [I, B; ESMO-MCBS v1.1 score: 3]. There is no general consensus preferring any of the four currently available first-line first- and second-generation EGFR TKIs over others [IV, C].

Osimertinib is a third-generation EGFR TKI that targets both sensitising *EGFR* mutation and the resistant exon 20 *T790M* mutation [186]. The drug was compared with a standard first-generation EGFR TKI (gefitinib or erlotinib) in the FLAURA phase III study [187]. Significant improvement in PFS was observed (mPFS 18.9 versus 10.2 months; HR 0.46, 95% CI 0.37–0.57, P<0.0001). Median second PFS (mPFS2) was not reached (NR) [95% CI 23.7–not calculable (NC)] in the osimertinib arm and 20.0 months (95% CI 18.2–NC) in the gefitinib or erlotinib arm (HR 0.58, 95% CI 0.44–0.78, P=0.0004) [187a]. More importantly, a similar degree of improvement was observed in the subgroup of patients.
with CNS metastasis (mPFS 15.2 versus 9.6 months, HR 0.47, 95% CI 0.30–0.74, P=0.0009). There was a clinically meaningful and statistically significant improvement in OS with osimertinib as first-line treatment for EGFR-mutated NSCLC [187b]. The median OS was 38.6 months (95% CI 34.5–41.8) in the osimertinib group and 31.8 months (95% CI 26.6–36.0) in the comparator group (HR 0.80, 95% CI 0.64–1.00, P=0.046). AEIs of grade 3 or higher were reported in 42% of the patients in the osimertinib group and in 47% of those in the comparator group. First-line osimertinib is now considered as the preferred option in first line for NSCLC patients with sensitising EGFR mutations [I, A; ESMO-MCBS v1.1 score: 4].

The combination of ChT with gefitinib, at progression with gefitinib, has not shown any clinical benefit (IMPRESS Trial) [188]. The NEJ009 trial is the first phase III study that evaluated the efficacy of a combination of EGFR TKI (gefitinib) and platinum doublet ChT (carboplatin/pemetrexed) in untreated advanced NSCLC patients with EGFR mutations [189]. Carboplatin/pemetrexed/gefitinib demonstrated significantly better PFS (mPFS 20.9 versus 11.2 months, HR 0.49, 95% CI 0.39–0.62) and OS (mOS 52.2 versus 38.8 months, HR 0.69, 95% CI 0.52–0.92) compared with gefitinib, in advanced EGFR-mutated NSCLC [I, B; not EMA-approved]. A second phase III study confirmed the potential benefit of the ChT (carboplatin/pemetrexed) combination with gefitinib in first-line therapy in EGFR-mutated NSCLC (mPFS 16 versus 8 months, HR, 0.51 (95 CI 0.39–0.66), P<0.001), mOS versus 17 months HR 0.45, 95% CI 0.31–0.65, P<0.001) [189a], representing a first-line therapy option [I, B; not EMA-approved].

The combination of EGFR TKI and antiangiogenesis was first investigated in Japan. A randomised phase II study compared the combination of erlotinib and bevacizumab with erlotinib alone as first-line therapy for patients with EGFR-mutant NSCLC. Seto et al. reported mPFS of 16.4 and 9.8 months (HR 0.52, 95% CI 0.35–0.76), respectively [II, A] [190, 191]. However, the significant difference of PFS did not translate into a difference of OS between these treatments (mOS 47 versus 47.4 months). A similar PFS was described in a European phase II trial that also evaluated the combination of erlotinib and bevacizumab, which was determined to be suitable as a front-line treatment option in EGFR-mutated NSCLC [II, B] [192]. A phase III trial (NEJ026) comparing bevacizumab/erlotinib to erlotinib in this patient population reported encouraging analysis results with significant benefit on PFS (mPFS 16.9 versus 13.3 months, HR 0.60, 95 CI 0.41–0.87); but no improvement in OS (mOS 50.7 versus 46.2 months with erlotinib with bevacizumab and erlotinib, respectively (HR 1.00, 95 CI 0.68–1.48) [I, A] [192a, 193].

While active research is ongoing, the EMA has approved the use of the combination of erlotinib and bevacizumab [I, A; ESMO-MCBS v1.1 score: 3]. Erlotinib/bevacizumab represents a front-line treatment option in EGFR-mutated tumours [I, A].

Ramucirumab (a human IgG1 VEGFR2 antagonist) in combination with erlotinib (versus erlotinib in combination with placebo) led to superior PFS (19.4 versus 12.4 months, HR 0.59, 95% CI 0.46–0.76, P=0.0001) in first-line EGFR-mutated NSCLC in a phase III trial [I, B; ESMO-MCBS v1.1 score: 3] [193a]. Safety was consistent with the established safety profiles of the individual compounds. Patients with brain metastases were excluded. OS was not increased in the experimental arm at interim analysis (HR 0.82, 95% CI 0.53–1.3) but data are still immature.

Beyond first-line treatment

Almost all patients who benefit from EGFR TKIs will eventually develop clinical resistance. About half of the resistance is explained by the acquired EGFR exon 20 T790M mutations [194]. Osimertinib and several other third-generation EGFR TKIs were developed targeting the T790M mutation. To date, the only approved medication for patients with T790M mutation is osimertinib. AURA3 is a randomised phase III study that compared osimertinib with pemetrexed/platinum in patients with proven T790M mutation at time of progression on first-/second-generation EGFR TKI [195]. Tumour ORR was 71% and 31%, respectively (HR 5.39, 95% CI 3.46–8.48, P<0.001). The primary endpoint of PFS was also significantly different (mPFS 10.2 versus 4.4 months; HR 0.30, 95% CI 0.23–0.41, P<0.0001). A numerical advantage in OS was observed for patients receiving osimertinib versus pemetrexed/platinum, with the majority of patients in the pemetrexed/platinum having crossed over to osimertinib. Median OS 26.8 months (95% CI 23.5–31.5) versus 22.5 months (95% CI 20.2–28.8), respectively, HR 0.87 (95% CI 0.67–1.12, P=0.277); survival rate at 24 months was 55% versus 43% and at 36 months was 37% versus 30% [195a]. Osimertinib also showed a significantly longer CNS PFS (11.7 months) and higher CNS ORR (70%, 95% CI 51–85) compared with ChT (CNS PFS 5.6 months, CNS ORR 31%, 95% CI 11–59) in patients with CNS metastases at baseline [196]. The probability of experiencing a CNS progression event was lower for osimertinib than for ChT at both 3 months (2.7% versus 8.2%, respectively) and 6 months (11.5% versus 28.2%, respectively). This study has established a new paradigm: all patients with clinical resistance to first-/second-generation EGFR TKIs should be tested for the presence of T790M mutation and osimertinib should be offered as standard treatment for patients who test positive [I, A; ESMO-MCBS v1.1 score: 4].

Molecular mechanisms of resistance to EGFR TKIs were complex and heterogenous in patients without T790M mutation. These include MET amplification, HER2 amplification, PIK3CA alternations, BRAF mutation, KRAS mutation and small cell transformation. The current standard in this scenario is platinum-based doublet ChT [I, A] and the expected ORR and PFS are 31% and 5.4 months, respectively [188]. This should be considered as a therapeutic option in patients with EGFR-mutated tumour, PS 0–1, in absence of contraindications to use of immunotherapy after targeted therapies have been exploited but often with limited benefit [III, A; not EMA-approved] [97, 196a].
Treatment of ALK-rearranged NSCLC

First-line treatment

The antitumour activity of crizotinib was initially demonstrated in two multicentre single-arm studies, with significant ORR and PFS advantages, as well as a survival advantage, compared with other treatment options [197, 198]. The phase III study, PROFILE 1014, compared crizotinib with platinum–pemetrexed (without maintenance pemetrexed) as first-line treatment in ALK-rearranged advanced NSCLC. It demonstrated a significantly longer PFS (mPFS 10.9 versus 7.0 months; HR 0.45; 95% CI 0.35–0.60; P<0.001) and higher ORR with crizotinib compared with ChT [199]. First-line treatment with crizotinib is a treatment option for patients with ALK-rearranged NSCLC [I, B; ESMO-MCBS v1.1 score: 4] (Figures 3 and 5).

Ceritinib and alectinib are second-generation ALK inhibitors that have shown robust antitumour efficacy, along with intracranial activity, in patients with ALK-rearranged NSCLC. The ASCEND-4 trial compared ceritinib (750 mg/day) with platinum-based ChT (cisplatin or carboplatin plus pemetrexed followed by maintenance pemetrexed) in untreated advanced ALK-rearranged non-squamous NSCLC [200]. Overall, ceritinib improved ORR over ChT: 72.5% (95% CI 65.5–78.7) compared with 26.7% (95% CI 20.5–33.7). mPFS was 16.6 months (95% CI 12.6–27.2) with ceritinib versus 8.1 months (95% CI 5.8–11.1) with ChT (HR 0.55, 95% CI 0.42–0.73, P<0.01). At baseline, 59 patients in the ceritinib arm and 62 patients in the ChT arm had CNS metastasis. Among them, the intracranial ORR by RECIST was 72.7% (95% CI 49.8–89.3) with ceritinib versus 27.3% (95% CI 10.7–50.2) with ChT. In patients without baseline brain CNS metastasis, the mPFS with ceritinib was 26.3 months (95% CI 15.4–27.7), versus 8.3 months (95% CI 6.0–13.7) in the ChT arm. The most common AEs (all grades) in the ceritinib group were diarrhoea (85%), nausea (69%), vomiting (66%) and an increase in alanine aminotransferase (ALT, 60%) [I, B; ESMO-MCBS v1.1 score: 4]. Considering the safety profile of ceritinib, the influence of food on its oral bioavailability and the fact that food may improve gastrointestinal tolerability, a trial was conducted with a lower dose of ceritinib taken with a low-fat meal (ASCEND-8) [201]. A 450 mg dose of ceritinib taken once daily with food provides similar systemic exposure as the currently approved daily dose of 750 mg in a fasted state, and preliminary safety results demonstrated a reduction of the gastrointestinal toxicities when compared with the 750 mg fasted dose. These results suggest this dosing regimen as an alternative to the ceritinib 750 mg fasted dose [III, B].

The efficacy of alectinib was tested in a phase III head-to-head trial comparing this molecule [300 mg twice daily (b.i.d.)] with crizotinib (250 mg b.i.d.) in ALK TKI-naive ALK-rearranged advanced NSCLC Japanese patients (J-ALEX trial), demonstrating the superiority of alectinib as an initial targeted treatment [202]. The PFS HR of the alectinib arm compared with the crizotinib arm was 0.34 (95% CI 0.17–0.70, P<0.0001). mPFS was NR [95% CI 20.3–not evaluable (NE)] in the alectinib arm, while it was 10.2 months (95% CI 8.2–12.0) in the crizotinib arm. A similar global trial in ALK-rearranged treatment-naïve patients was conducted (ALEX trial). Patients were randomised to receive either alectinib (600 mg b.i.d.) or crizotinib (250 mg b.i.d.) [53]. The investigator-assessed mPFS with alectinib was 34.8 (95% CI 17.7–NR), compared with 10.9 months (95% CI 9.1–12.9) with crizotinib [202, 203a]. PFS assessed by the independent review committee was also significantly longer with alectinib than with crizotinib (mPFS 25.7 months; 95% CI 19.9–NE versus 10.4 months; 95% CI 7.7–14.6, respectively). In patients with baseline CNS metastases, mPFS was 27.7 months for alectinib versus 7.4 months for crizotinib. The time to CNS progression was significantly longer with alectinib than with crizotinib (cause-specific HR 0.16, 95% CI 0.10–0.28, P<0.0001). The updated ALEX study results revealed a 5-year survival rate of 62.5% (95% CI 54.3–70.8) in the alectinib treatment group, versus 45.5% (95% CI 33.6–57.4) [203b]. The OS data remain immature, with 37% of events recorded (stratified HR 0.67, 95% CI 0.46–0.98). Grade 3–5 AEs were less frequent with alectinib (41% versus 50% with crizotinib) [I, A; ESMO-MCBS v1.1 score: 4]. In the phase 3 randomised ALESIA trial, only Asian patients (187 patients) were recruiting to compare alectinib with crizotinib as a first-line treatment for ALK-rearranged NSCLC [203c]. Investigator-assessed PFS was significantly prolonged with alectinib versus crizotinib (HR 0.22, 95% CI 0.13–0.38, P<0.0001; mPFS NE versus 11.1 months). Independent review committee-assessed PFS was also significantly longer in the alectinib group compared with the crizotinib group (HR 0.37, CI 0.22–0.61, P<0.0001).

In the open-label ALTA-1L trial, 275 patients were randomised between brigatinib 180 mg once daily after a 7-day lead-in at 90 mg or crizotinib [215]. At second interim analysis, median follow-up was 24.9 months in the brigatinib group and 15.2 months in the crizotinib group. Estimated PFS at 12 months was 67% in the brigatinib group versus 43% in the crizotinib group (HR 0.49, P<0.001). Blinded, independent review committee-assessed mPFS (primary endpoint) was 24.0 versus 11.0 months (HR 0.49; 95% CI 0.35–0.68) [215a]. HRs consistently favoured brigatinib across subgroups. On investigator assessment, PFS at 2 years was 56% versus 24% (HR 0.43, 95% CI 0.31–0.61) [I, A; not EMA-approved]. The confirmed intracranial response rate among 41 patients with measurable lesions was 78% versus 26% (ORR 11.67, 95% CI 2.15–63.27); the intracranial response rate among all 96 patients with brain lesions was 66% versus 16% (ORR 11.75, 95% CI 4.19–32.91) [215].

Recently, ensartinib, a potent new-generation ALK inhibitor, has similarly shown an improvement in PFS compared with frontline crizotinib in the xALTo phase 3 randomised trial [215b]. 290 patients were randomised between ensartinib 225 mg once daily and crizotinib 250 mg twice daily, with an improvement in mPFS from 12.7 months for crizotinib to 25.8 months for ensartinib (HR 0.51), and an improved HR of 0.45 in patients with centrally confirmed ALK positivity by FISH. The intracranial activity strongly favoured ensartinib [I, A; not EMA-approved].

In patients with CNS involvement, front-line use of ALK TKIs is effective, and alectinib [III, A] or ceritinib [IV, B] is recommended, while interim analysis of ALTA-1L brigatinib data establish this drug in this setting too [III, A; not EMA-approved]. While ceritinib represents a better treatment strategy than ChT [I, B] and presumably crizotinib [IV, B],...
alectinib represents an EMA-approved better treatment option than ChT [III, A] and crizotinib [I, A; ESMO-MCBS v1.1 score: 4]. At first analysis,brigatinib presented with more favourable outcomes than crizotinib [I, A; not EMA-approved]. Lorlatinib is currently in phase III testing to investigate whether upfront treatment with this next-generation TKI can further improve clinical outcomes for patients with advanced ALK-rearranged NSCLC compared with crizotinib treatment [I, A; not EMA-approved] [213].

Beyond first-line treatment

The benefit of crizotinib over second-line ChT in TKI-naive patients with previously treated ALK-rearranged NSCLC was confirmed in the phase III PROFILE 1007, with better ORR and PFS [204]. The mPFS was 7.7 months (95% CI 6.0–8.8) in the crizotinib group, compared with 3.0 months (95% CI 2.6–4.3) in the ChT group. Any patient with NSCLC harbouring an ALK fusion should receive crizotinib as next-line therapy, if not received previously [I, A]. Despite improved outcome in patients with tumours harbouring ALK rearrangements and treated with crizotinib (mainly in first line), all patients will eventually experience disease progression through primary or acquired resistance. Furthermore, crizotinib penetration into the cerebrospinal fluid (CSF) is negligible, and this pharmacological limitation is extremely relevant in treatment decisions, taking into account the high propensity of ALK-rearranged NSCLC to metastasise to the brain [205]. Ceritinib (ASCEND-5) and alectinib (ALUR) were compared with ChT in patients with ALK-positive NSCLC previously treated with crizotinib and ChT [206, 207]. Both trials showed a significant improvement in mPFS compared with ChT (5.4 months, 95% CI 4.1–6.9 for ceritinib versus 1.6 months, 95% CI 1.4–2.8 for ChT; HR 0.49, 95% CI 0.36–0.6, P<0.001) and 9.6 months, 95% CI 6.9–12.2 for alectinib versus 1.4 months, 95% CI 1.3–1.6 for ChT; HR 0.15, 95% CI 0.08–0.29; P<0.001). CNS ORR was 54.2% and 35% with alectinib or ceritinib, respectively, versus 0% or 5% with ChT in the ALUR and ASCEND-5 trials, respectively [206–208]. Based on this data, ceritinib and alectinib are recommended in patients with ALK-positive advanced NSCLC who progress on treatment with or are intolerant to crizotinib [I, A; ESMO-MCBS v1.1 score: 4].

The next-generation ALK inhibitors, such as alectinib, brigatinib or lorlatinib, have an improved affinity for ALK and a wide coverage of ALK secondary resistance mutations, and sequential therapy with these ALK inhibitors represent additional treatment options in crizotinib-resistant populations. The ALTA trial evaluated brigatinib in crizotinib-resistant ALK-rearranged NSCLC patients. Patients were randomised (1:1) to receive oral brigatinib 90 mg once daily (arm A) or 180 mg once daily with a 7-day run-in at 90 mg (arm B) [209, 209a]. With an 8.0 month median follow-up, the ORR was 45% (97.5% CI, 34%–56%) in arm A and 54% (97.5% CI, 43%–65%) in arm B and mPFS was 9.2 months in arm A and 12.9 months in arm B. mOS was NR in arm A and was 27.6 months in arm B. CNS ORRs were 50% and 67% in arms A and B, respectively. These data resulted in a recent EMA approval, and brigatinib represents an additional treatment option at crizotinib resistance [III, A; ESMO-MCBS v1.1 score: 3].

In results from a phase I study, lorlatinib demonstrated significant activity reporting ORRs of 46% and 42% among ALK-rearranged patients pretreated with two or more ALK TKIs, respectively, including patients with CNS metastases at baseline (intracranial ORR 42%) [210]. A phase II study at the recommended dose (100 mg once a day) demonstrated an objective response in 72.9% of patients who had only received previous crizotinib, 42.9% of patients with one previous non-crizotinib ALK tyrosine kinase inhibitor (EXP3B), and 39.6% of patients with two or more previous ALK tyrosine kinase inhibitors [211, 211a]. Of interest, in patients previously treated with one or more second-generation ALK TKIs, a high proportion of patients harbouring an ALK secondary mutation responded to treatment with lorlatinib, while those without detectable ALK mutations were still presenting a clinically meaningful benefit [62% versus 32% (plasma); 69% versus 27% (tissue)] [212, 212a]. PFS was similar in patients with and without ALK mutations on the basis of plasma genotyping (mPFS 7.3 months versus 5.5 months, HR 0.81) but significantly longer in patients with ALK mutations identified by tissue genotyping (mPFS 11.0 months versus 5.4 months, HR 0.47). The results of the study led to a new EMA approval for use of lorlatinib in patients whose disease has progressed after alectinib or ceritinib as the first ALK TKI therapy, or crizotinib and at least one other ALK TKI in May 2019 [III, A; ESMO-MCBS v1.1 score: 3] [211a, 212a].

In ALK-rearranged patients progressing on crizotinib, treatment with next-generation ALK TKIs, such as alectinib [I, A], ceritinib [I, A] or lorlatinib [II, A], is recommended.

Ensartinib possesses a high activity against a broad range of known crizotinib-resistant ALK mutations and CNS metastases, which also showed potential post-crizotinib efficacy [215c].

In patients who progress after a second-generation ALK TKI, the next-generation ALK inhibitor lorlatinib is recommended [III, A].

Treatment of ROS1-rearranged NSCLC

On the basis of the available preclinical data, the phase I PROFILE 1001 study of crizotinib was amended to include patients with ROS1-rearranged NSCLC in the expansion cohort [216]. Among 50 patients with ROS1-rearranged NSCLC in this trial cohort, the ORR to crizotinib was 72%, with a disease control rate equal to 90% and an mPFS of 19.2 months. In a prospective French phase II study and in the retrospective EURO51 study of crizotinib for ROS1-rearranged NSCLC, mPFS was 10 and 9.1 months and ORR was 72% and 80%, respectively, although both of these studies enrolled only approximately 30 patients [217, 218]. In a larger East Asian phase II study of crizotinib, the mPFS among 127 patients with ROS1-rearranged lung cancer was 13.4 months [219]. Each study included patients who had received varying numbers of prior lines of systemic therapy, although for all of these patients, crizotinib remained the first ROS1-directed TKI. Single-agent crizotinib is recommended in the first-line setting or as second line in patients with stage IV NSCLC with ROS1 rearrangement [III, A; ESMO-MCBS v1.1 score: 3] (Figures 3 and 6).
patients have received crizotinib in the first-line setting, then they may be offered platinum-based ChT therapy in the second-line setting [IV, A].

Ceritinib is a potent and selective ALK inhibitor that also inhibits ROS1. In a Korean phase II study, 32 patients with ROS1-rearranged advanced NSCLC were treated with ceritinib, 750 mg daily [220]. Among crizotinib-naive patients, the ORR was 67%, with a disease control rate of 87%. The mPFS was 9.3 months for the entire cohort and reached 19.3 months for crizotinib-naive patients. Of note, in those two patients who had received prior crizotinib, no clinical response was observed. Ceritinib might be considered in crizotinib-naive patients but is currently not approved by the EMA [III, C].

Lorlatinib is a potent, brain-penetrant, third-generation TKI that targets ALK and ROS1 with preclinical activity against most known resistance mutations in ROS1. In an open-label, single-arm, phase I–II trial, 69 patients with ROS1-positive NSCLC were enrolled, 21 (30%) of 69 patients were TKI-naive, 40 (58%) had previously received crizotinib as their only TKI and eight (12%) had previously received one non-crizotinib ROS1 TKI or two more ROS1 TKIs [220a]. 14 (35%; 21–52) of 40 patients previously treated with crizotinib, as their only TKI had an objective response. Intracranial responses were achieved in seven (64%; 95% CI 31–89) of 11 TKI-naive patients and 12 (50%; 29–71) of 24 previous crizotinib-only patients [III, B].

An integrated analysis of three ongoing phase I or II trials of entrectinib (ALKA-372-001, STARTRK-1 and STARTRK-2), showed 41 (77%; 95% CI 64–88) of 53 patients with a ROS1-rearranged NSCLC in the efficacy-evaluable population had an objective response [220b]. Median duration of response was 24.6 months (95% CI 11.4–34.8). In August 2020, the EMA approved a conditional marketing authorisation to entrectinib for the treatment of NSCLC patients positive for ROS1 mutations (patients who have not previously received other ROS1 inhibitors) [III, B; ESMO-MCBS v1.1 score: 3] [220c].

Repotrectinib is a next-generation ROS1/TRK/ALK TKI with higher potency versus crizotinib against ROS1. Preclinical studies demonstrate robust activity against all known ROS1 resistance mutations, including the most common solvent-front mutations ROS1 G2032R. In the phase I (TRIDENT-1 study), 11 evaluable TKI-naive ROS1-rearranged NSCLC patients, confirmed ORR by blinded central review (BCR) was 91% (95% CI 59–100) [220d]. In 18 ROS1-rearranged NSCLC patients pretreated with 1 prior TKI, confirmed ORR by BCR was 39% (95% CI 17–64). All patients with ROS1 G2032R had tumour regression [confirmed ORR of 40% (n = 2/5)] [III, B].

Lorlatinib, repotrectinib and entrectinib have potential anti-ROS1 activity on the basis of preclinical studies and limited phase I/II encouraging clinical data [220d, 221, 221a, 221b] [III, B].

### Treatment of BRAF-mutated NSCLC

The most common BRAF mutation, V600E (Val600Glu), is observed in 1%–2% of lung adenocarcinomas [222–224], more frequently in patients with smoking history. In a retrospective multicentre cohort study in Europe, patients with advanced BRAF-mutant lung cancer received treatment with either vemurafenib (n=29), dabrafenib (n=9) or sorafenib (n=1) [225]. Of the BRAF mutations, 83% were BRAF V600E. The ORR was 53% and the PFS and OS were 5 and 10.8 months, respectively.

In a vemurafenib basket trial (VE-BASKET), patients with various BRAF V600 mutation-positive non-melanoma tumours were enrolled in six prespecified cancer cohorts, including an NSCLC cohort with 20 patients [226]. A total of 19 NSCLC patients were evaluable for response. Overall, one patient was treatment-naive and 50% and 45% of patients received one or two or more lines of therapy before study inclusion, respectively. The ORR, mPFS and mOS were 42%, 7.3 months and NR, respectively.

A prospective multicentre multicohort phase II study of dabrafenib monotherapy (cohort A), or combination therapy with a MEK inhibitor (trametinib) (cohort B, beyond first-line and cohort C in first-line treatment) in patients with BRAF V600E-mutant metastatic NSCLC (BRF113928) was reported. With dabrafenib monotherapy (cohort A, n=78), the ORR was 33% and mPFS and median duration of response (mDoR) were 5.5 and 9.6 months, respectively [227]. With combination dabrafenib and trametinib in pretreated patients (cohort B, n=57), the ORR was 66% and mPFS and mDoR were 10.2 and 9.8 months, respectively [228, 229]. With combination dabrafenib and trametinib therapy in untreated patients (cohort C, n=36), the ORR was 64% and mPFS and mDoR were 10.9 and 10.4 months, respectively [230]. The mOS was 17.3 months (95% CI 12.3–40.2; 3-year OS: 40%) and 18.2 months (95% CI 14.3–28.6; 3-year OS: 33%) with 14/36 and 11/57 patients alive in treatment-naive (cohort C) and pretreated (cohort B) patients, respectively [230a]. The EMA and the United States FDA have approved dabrafenib in combination with trametinib for the treatment of patients with BRAF V600 mutation-positive advanced or metastatic NSCLC. BRAF/MEK inhibition using dabrafenib with trametinib is recommended in patients with BRAF inhibitor-naive, stage IV NSCLC with BRAF V600E mutation [III, A; ESMO-MCBS v1.1 score: 2] (Figures 3 and 7). If patients have received BRAF/MEK inhibition in the first-line setting, then they may be offered platinum-based ChT in the second-line setting [IV, A].

### Treatment of NSCLC with other actionable oncogenic drivers

Several other molecular targets have been identified harbouring somatic variants with therapeutic potential, including RET, MET, HER2 and NTRK.

RET fusions are found in 1%–2% of NSCLC and tend to be mutually exclusive to other lung cancer drivers [231, 232]. Although RET-selective inhibitors have not yet been developed, several multtarget agents with anti-RET activity have been evaluated in preclinical models and clinical trials. The activity of multit kinase inhibitors (caborzantinib, vandetanib, sunitinib, sorafenib, alec tinib, lenvatinib, nintedanib, ponatinib and regorafenib) in patients with RET-
Updated version published 15 September 2020 by the ESMO Guidelines Committee

rearranged NSCLC (ORR 16%–47% and mPFS 2.3–7.3 months) is clearly inferior to the responses and survival outcomes seen with selective TKIs in other oncogene-addicted NSCLC models [233–236]. These studies are small and subject to selection bias and results of heterogeneous benefit [III, C] [237]. In contrast, selipcatinib (LOXO-292) and pralsetinib (BLU-667) selectively block RET, avoiding other targets and the associated treatment-limiting side effects. Both RET inhibitors are currently in late-stage clinical trials, and pralsetinib was approved by the FDA in September 2020 for the treatment of adults with metastatic RET-fusion-positive NSCLC [237a]. Updated data from selipcatinib and pralsetinib in patients with advanced RET-fusion-positive NSCLC demonstrate potent, durable and broad antitumour activity, with treatment being well tolerated. In the phase I/II ARROW study with pralsetinib, the ORR among 116 response-evaluable patients was 65% (95% CI 55–73), and 61% ORR in patients (n=80 patients) previously treated with platinum ChT. mDOR was not yet reached (95% CI; 11.3 months to not reached) [237b]. Intracranial ORR in 9 patients with measurable CNS metastases at baseline was 56%. In the phase I/II LIBRETTO-001 study, the selipcatinib produced an ORR by investigator assessment of 70% (95% CI 59.8–78.1) in 105 patients previously treated with platinum-based ChT, and 90% (95% CI 75.8–97.1) ORR in 39 treatment-naive patients [237c]. mDOR was 20.3 months (95%CI 15.6–24.0) and not reached in previously treated and treatment-naive patients, respectively. Randomised phase III trials of selipcatinib/pralsetinib versus platinum-pemetrexed ChT with or without pembrolizumab are planned or are ongoing (NCT04222972, NCT04194944). Targeting RET can be recommended if selipcatinib or pralsetinib is available in late lines of treatment [III, B]; however, recruitment into open trials is encouraged.

Somatic dysregulation at MET occurs through a number of different non-exclusive mechanisms in NSCLC including overexpression, amplification, mutation and gene rearrangement. Previous trials aimed at targeting MET overexpression (e.g. onartuzumab or tivantinib) have failed, and as the relationship between expression and genomics is now better understood, focus has shifted to targeting genomic variants [238–240]. Two major MET variants may play a key role as NSCLC oncogenic drivers: MET exon 14 variants (METex14) and MET amplification. MET amplification can occur as either acquired (as a resistance mechanism to EGFR TKI therapy) or de novo. While a promising target, targeting MET dysregulation by MET amplification is not currently routinely recommended and recruitment into open trials is encouraged [III, C]. METex14 mutations are similarly as common as ALK rearrangements, occurring in 3%–4% of NSCLC. They are more frequently but not exclusively identified in adenocarcinoma and sarcomatoid carcinoma histological subtypes (especially those with an adenocarcinoma component), observed in current, ex- and never-smokers, more frequently observed in older than in younger patients. METex14 mutations are extremely diverse and result in aberrant splicing and exon 14 skipping, resulting in loss of the METY1003 c-Cbl binding site and reduced MET degradation, detectable as increased expression by IHC. However, METex14 mutations are mutually exclusive to other drivers (EGFR, ALK, BRAF), further reinforcing MET status as an oncogenic driver, more often encountered in smokers. Multiple case series and cohorts have now demonstrated durable ORRs with MET-targeting TKIs including crizotinib, capmatinib and tepotinib in METex14 patients, with the PROFILE 1001 trial METex14 cohort reporting an ORR of 32% [the mDOR was 9.1 months (95% CI 6.4–12.7) and the median PFS was 7.3 months (95% CI 5.4–9.1)] and a global retrospective series demonstrating a PFS of 7 months, both with crizotinib [241, 241a, 242]. For METex14 variants, crizotinib has demonstrated potential clinical efficacy that needs to be confirmed [III, B]. A variety of more specific MET-directed TKIs are undergoing development against this target (i.e. capmatinib, tepotinib, salvotinib).

Single-arm phase II trials of tepotinib or capmatinib have demonstrated clinically meaning efficacy in NSCLC patients harbouring METex14 mutations [III, B]. The ORR was 48% (95% CI 36–61) among 66 patients in the liquid-biopsy group and 50% (95% CI 37–63) among 60 patients in the tissue-biopsy group treated with tepotinib [242a]. The response rate by an independent review committee was 46% (95% CI 36–57), with a mDOR of 11.1 months (95% CI 7.2 could not be estimated) in the combined-biopsy group. Capmatinib showed 41% (95% CI 29–53) ORR by independent review committee in cohort 2/3 line (69 patients) and 68% (95% CI 48–84) in cohort first line (28 patients) with a mDOR of 9.7 and 12.6 months, respectively [242b]. Overall response was observed in 41% (95% CI 29 to 53) of 69 patients who had received one or two lines of therapy previously and in 68% (95% CI 48 to 84) of 28 patients who had not received treatment previously; the mDOR was 9.7 months (95% CI 5.6 to 13.0) and 12.6 months (95% CI 5.6 to NE), respectively [242a, 242b].

HER2 dysregulation is another promising target for advanced NSCLC and is abrogated via different mechanisms including exon 20 mutations, transmembrane domain mutations, amplification and protein overexpression. Mutations in exon 20 were the first HER2 mutations described and occur in 1%–5% of patients, over-represented in young patients, never-smokers, females, patients without ethnic clustering and typically in adenocarcinomas [243]. Such mutations are analogous to EGFR exon 20 insertions, being mutually exclusive to other oncogenic drivers, and are usually 3–12 bp in-frame insertions between codons 775–881, the most common being the YVMA insertion at codon 775. HER2 insertions are typically resistant to HER-targeting TKIs afatinib, dacomitinib and neratinib [244, 245], although some specific genotypes, e.g. those resulting in Gly770 insertion, may retain sensitivity [246]. Afatinib and poziotinib have demonstrated some activity in HER2-mutated NSCLC in small series [247, 248]. More recently, targeting HER2 mutation with adotrastuzumab emtansine (TDM-1) has shown promise with two cohorts demonstrating responses including mutants with no copy-number change [249]. Trastuzumab deruxtecan is a novel antibody-drug conjugate composed of an anti-HER2 antibody, cleavable tetrapeptide-based linker and topoisomerase I inhibitor payload. In a phase I trial, patients with HER2-mutated NSCLC who received trastuzumab deruxtecan had a confirmed ORR of 72.7% (8/11) [249a]. DESTINY-Lung01 (NCT03057510) is an ongoing, multicentre, phase 2 study of trastuzumab deruxtecan in patients with non-squamous NSCLC overexpressing HER2 or containing a HER2-activating mutation. Interim results for the cohort with HER2 mutations after a median follow-up of 8.0 months (range, 1.4–14.2 months) have been reported [249b]. Confirmed ORR by independent review committee among the 42 patients was 61.9% (95%
CI 45.6%–76.4%); median DOR was not reached at data cut-off (DCR), which was 90.5% (95% CI, 77.4%–97.3%); and estimated median PFS was 14.0 months (95% CI 6.4–14.0 months). Its use is mainly restricted to clinical trials, while activity is promising [III, B]. Abnormal gene copy-number is also identified at HER2, although it is typically polysomy, with HER2 exon 20 insertions and amplification usually mutually exclusive [243]. Targeting HER2 amplification or protein expression with trastuzumab monotherapy has not consistently demonstrated benefit, but may have a role in HER2-mutant NSCLC, although data are usually based on cases confounded by concurrent ChT and variable HER2 expression. The antibody–drug conjugate TDM-1 has shown very modest activity in HER2-overexpressing NSCLC [250]. Rarer HER2 variants include transmembrane domain mutations (e.g., V659, G660) that have reported sensitivity to afatinib and TDM-1 [251]. Nevertheless, given the paucity of robust data, targeting HER2 dysregulation is not currently recommended and recruitment into open trials is encouraged [III, C].

Somatic fusions involving the neurotrophic tyrosine receptor kinase genes (NTRK1-3) are rare oncogenic drivers occurring at low prevalence (<1%) in a variety of tumours including NSCLC [252], again typically in adenocarcinomas (although non-adenocarcinoma cases are reported) and never-smokers [252a]. The rarity of these NTRK gene fusions across different cancer types has resulted in basket trial design for drug development. NRTK1-3 gene fusions encode oncogenic TRKA-C fusion proteins, respectively, that can be targeted by therapies, including larotrectinib (LOXO-101) and entrectinib (RXDX-101) [253–256]. Both have demonstrated marked durable responses in NTRK fusion-positive NSCLC in single-arm basket studies. An integrated database comprised the pivotal datasets of three, ongoing phase I or II clinical trials (ALKA-372-001, STARTTRK-1 and STARTTRK-2), which enrolled patients with metastatic or locally advanced NTRK who received entrectinib. Of 54 patients had an objective response, four (7%) were complete responses and 27 (50%) partial responses. mDOR was 10.4 months. (95% CI 7.1 to NE). Entrectinib showed promising clinical activity in this rare disease entity with the treatment of 10 NSCLC and a RR of 70% for a PFS of 14.9 months, deserving further evaluation [256a]. In August 2020, the EMA granted a conditional marketing authorisation to entrectinib for the treatment of solid tumours expressing NTRK gene fusions [III, B; ESMO-MCBS v1.1 score: 3] [220c].

Results of a phase I study involving adults, a phase I–II study involving children, or a phase II study involving adolescents and adults showed larotrectinib induced an ORR of 75% (95% CI 61–85) by independent review and 80% (95% CI 67–90) by investigator assessment in 55 evaluable patients [220b]. An update on 159 patients report an ORR of 79% (95% CI 72–85), a mPFS of 28.3 months (95% CI 22.1–NE) and a mOS of 44.4 months (95% CI 36.5–NE) [256b].

In September 2019, the European Commission approved larotrectinib for the treatment of adult and paediatric patients with solid tumours that display a NTRK gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity and who have no satisfactory treatment options. This makes larotrectinib the first tumour-agnostic drug to be approved in the European Union [III, A; ESMO-MCBS v1.1 score: 3]. Larotrectinib is recommended in NTRK gene fusion patients with advanced NSCLC who were previously treated [III, B].

KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumours. The KRAS(G12C) mutant has a cysteine residue that has been exploited to design covalent inhibitors that have promising preclinical activity. KRASG12C is present in approximately 13% of lung adenocarcinoma. AMG 510 is a first-in-class oral KRAS(G12C) inhibitor with evidence of clinical activity in patients with KRASG12C-mutant cancer [256c]. Preclinically, AMG 510 selectively-targeted KRASG12C tumours caused durable regression as a monotherapy. ORR across all 23 NSCLC patients was 48%, with all responders achieving a partial response [256d]. Among the 13 participants who received the recommended phase II dose of 960 mg/day, the ORR was 54%, and again all responses were partial. Forty-six percent of patients had stable disease and no patient progressed, which equated to a DCR of 100%. These data continue to show encouraging antitumour activity with AMG 510. Other specific KRAS G12C small molecules inhibitors are currently being investigated, such as MRTX849 and JNU-74699157.

For KRAS(G12C)-mutant, recruitment into open trials is encouraged [III, C].

Role of radiotherapy in stage IV NSCLC

External beam radiotherapy (EBRT) plays a major role in the symptom control of metastases, such as painful chest wall disease, painful bone metastasis, superior vena cava syndrome, soft tissue or neural invasion. EBRT is indicated in cases of haemoptysis and symptomatic airway obstruction [III, B]. A Cochrane systematic review of palliative EBRT regimens for patients with thoracic symptoms from NSCLC included 14 RCTs (3576 patients) [257]. Doses of radiation ranged from 10 Gy in 1 fraction to 60 Gy in 30 fractions, with a total of 19 different dose/fractionation regimens. There was no strong evidence that any regimen achieved a greater level of palliation [II, B]. Furthermore, higher dose regimens were associated with higher rates of acute toxicity. However, it should be noted that the studies were heterogeneous and most were conducted in the 1980s and 1990s, therefore using dated radiotherapy (RT) techniques. There are few data on the optimal timing of thoracic RT and systemic therapy in the stage IV NSCLC setting. Furthermore, there is no evidence to-date that the concurrent administration of ChT, targeted agents or immunotherapy to palliative RT is beneficial in this group of patients.

Another method of palliation of thoracic symptoms is endobronchial brachytherapy (EBB). The effectiveness of EBB compared with EBRT or other alternative endoluminal treatments was assessed in a Cochrane systematic review [258]. The authors concluded that EBRT alone is more effective for palliation than EBB alone [II, B]. However, evidence was limited with regard to the comparison of EBB plus EBRT over EBRT alone for symptom relief. For patients previously...
Focus on brain metastases

CNS metastases are commonly identified with NSCLC, predominantly with adenocarcinoma. LMD is a deadly complication of solid tumours and is associated with a poor prognosis. Adenocarcinomas are the most common tumours to metastasise to the CNS. Of the patients with NSCLC, 30%–64% have CNS metastases, of which 4%–7% present LMD [260]. Incidence and prevalence of LMD are both increasing due to brain metastases screening, better imaging modalities as well as prolongation of patients’ survival.

Presence of malignant cells on CSF cytology provides the gold-standard for diagnosing leptomeningeal (LM) carcinomatosis. Abnormalities on imaging can be found in 70%–80% of patients with LMD and the imaging modality of choice is high quality, T1-weighted MRI with gadolinium contrast, which has been shown to be more sensitive compared with contrast-enhanced CT [261, 262].

The treatment of patients with brain metastases, with/without LM involvement and no driver mutations, is dependent on the prognosis. Prognosis can be estimated based on the Radiation Therapy Oncology Group recursive partitioning analysis (RPA); class I patients are those < 65 years old, with a good PS (Karnofsky Index (KI) ≥ 70%), no other extracranial metastases and a controlled primary tumour; class III patients have a KI < 70%; and class II represents all other patients [263]. In RPA class III patients, RT is not recommended in view of the dismal prognosis [I, A]; only BSC is recommended, as their median survival is generally < 2 months. The role of whole-brain RT (WBRT) in unselected patients has been questioned by the QUARTZ trial data, in which patients were randomised to either BSC including dexamethasone plus WBRT 20Gy in 5 daily fractions or to the same BSC without WBRT [264]. This trial demonstrated no difference between the treatment arms regarding the relief of symptoms, steroid use, OS, QoL or quality-adjusted life years in the intention-to-treat (ITT) population, confirming no benefit for WBRT in the RPA class III subset [I, A]. However, the median survival in the trial was poor (8.5–9.2 weeks) and the trial recruited over 7 years, a time during which considerable advances in molecular selection, systemic therapy, stereotactic radiosurgery (SRS) patient selection and MRI brain surveillance have been implemented. A signal for WBRT benefit was seen for younger patients with better Karnofsky PS and either controlled primary or no extracranial disease. WBRT can therefore be considered for patients contingent on prognostic factors of better survival such as driver mutations [II, C].

The most frequent WBRT schedules are 20Gy in 5 fractions or 30 Gy in 10 fractions, with no difference in outcome [I, A] [265]. For most patients with symptomatic brain metastases and/or significant oedema, dexamethasone or equivalent corticosteroid is recommended [III, A] [266]. Tapering of the dose and, if possible, cessation after RT, are recommended. Corticosteroids are not recommended in the case of asymptomatic brain metastases. WBRT may be associated with delayed progressive cognitive impairment in responders, as tumour progression affects this parameter more than radiation toxicity [267]. Neuroprotective agents have not shown a convincing role and are not recommended for routine use [II, C], with a small phase III trial of memantine on 149 assessable patients (RTOG 0614) suggesting benefit [268]. Hippocampus avoidance WBRT has been shown to be probably safe [269], but is still undergoing trial evaluation and is not currently recommended for routine care [III, C].

Recent data showed that SRS can be considered as another standard of care for this patient population as a less toxic alternative to WBRT. SRS of the surgical cavity in patients who have had complete resection of 1–3 brain metastases significantly lowers local recurrence compared with that noted for observation alone [270].

In case of single brain metastases surgical resection can be considered [III, B] [271–273]. Postoperative WBRT or SRS is generally recommended after surgical resection [I, A] [274].

Another treatment strategy, in the case of a limited number of metastases and RPA class I and II, is SRS alone [III, B] [275–278]. The randomised trials evaluating SRS have included patients with 1–4 brain metastases. SRS has increasingly become the favoured modality due to reduced morbidity compared with WBRT, but it should be noted that there is no randomised trial comparing SRS alone to WBRT. A survival advantage in favour of WBRT plus SRS has been demonstrated against WBRT but only for the subgroup of patients with a single brain metastasis [279]. The majority of studies evaluating WBRT in addition of SRS or neurosurgery have shown a decline in cognitive function in the combined arm [278, 279]. SRS alone with close follow-up, without WBRT consolidation, is therefore a recommended strategy [III, B].

Although it is generally accepted that SRS should generally be considered in patients with ≤ 4 brain metastases, a prospective observational study from Japan challenged this prevailing concept [280]. The study enrolled 1194 eligible patients (76% had lung cancer) with 1 to 10 newly diagnosed brain metastases, longest diameter < 3 cm, largest tumour < 10 mL in volume and a total cumulative volume of ≤ 15 mL. OS did not differ between patients treated with SRS with 2–4 metastases and those with 5–10 metastases. This study therefore suggested the use of tumour volume and absolute size, rather than the number of metastases, as treatment criteria. In some territories, the indication for SRS is now based on total tumour volume rather than number of metastases, as the risk of radionecrosis increases with tumour volume [III, C] [278]. In patients undergoing SRS, radionecrosis is a challenging complication to manage.

In patients with asymptomatic brain metastases who have not yet received prior systemic therapy (i.e. ChT, TKIs), treatment with upfront systemic therapy and deferred RT should be considered, with trial data suggesting similar intracranial and extracranial ORRs [II, B] [281, 282]. In patients suitable for first-line immune-checkpoint inhibitor therapy, CNS metastases were generally mandated to have been treated before therapy, with evidence of intracranial
response. There is currently limited trial data demonstrating safety and efficacy of immunotherapy in patients with small-volume untreated CNS metastases [III, B] [283]. Among those patients with an actionable oncogenic driver (e.g. EGFR, ALK), between 44% and 60% develop brain metastases in the course of their disease [284, 285]. In such patients, the use of CNS-penetrant next-generation TKIs (e.g. osimertinib, alecinib, ceritinib) may restore control of brain disease, thereby potentially delaying cranial RT [II, A] [53, 187, 200]. Moreover, next-generation TKIs may also reduce the incidence of new CNS metastases, thereby significantly postponing the time to need CNS RT [53].

Focus on LM carcinomatosis
LMD may present with non-specific neurological symptoms (headaches, nausea, vomiting) as well as discrete signs due to the CNS area involved (gait difficulties, cranial nerve palsies), and a high index of suspicion is required, particularly in those with actionable oncogenic drivers due to higher prevalence [V]. Diagnostic modalities include cerebrospinal MRI with contrast enhancement, ideally before CSF intervention. CSF sampling with cytological assessment is diagnostic but limited by low sensitivity but high specificity [IV, A]. The prognosis from LMD due to NSCLC is poor, and treatment aim is to prolong survival with acceptable QoL. Patients with actionable oncogenic drivers may derive benefit from a CNS-penetrant next-generation TKI as per those with brain metastases [III, B]; otherwise, systemic therapy strategies vary widely across Europe. ChT and bevacizumab may have activity both extracranially and intracranially, and also in the context of LMD [IV, C] [126, 286]. Intra-CSF pharmacotherapy may be considered through either repeated lumbar punctures, a reservoir or ventricular device, although consideration should be given to patient factors, e.g. PS, extracranial control and likely benefit [V, C]. No randomised data exist to support the role of RT for LMD. In exceptional cases, focal RT can be considered for circumscribed, notably symptomatic, lesions [V, C].

Role of surgery in stage IV NSCLC
As prognosis in the majority of patients with stage IV NSCLC is poor, the role of surgery is traditionally limited in this patient group. However, with the widespread introduction of targeted therapies and immunotherapy improving prognosis in specific subcategories, the role of thoracic surgery is currently redefined. At the present time, surgery may be indicated for diagnostic evaluation of response to systemic therapy and palliation, and highly selected patients may be considered for lung resection with therapeutic intent or even for a salvage procedure. In the last two categories, surgery can be carried out with a mortality < 2%, a low morbidity rate and 5-year survival rates in the range of 11%–30% in retrospective series [IV, C] [287, 288]. Whether there is a significant difference between synchronous and metachronous metastases and between different distant sites has not been clearly established and more prospective data are needed.

When metastatic disease is suspected on PET scanning, invasive surgical procedures such as incisional biopsies, mediastinoscopy, thoracoscopy (VATS) or laparoscopy may be required to obtain relevant biopsy samples. Examples include patients with contralateral lung nodules, distant metastases or suspicion of mediastinal nodal involvement who do not qualify for minimally invasive biopsies or in whom results of the latter are equivocal. Adequate samples should be provided to the pathologist for detailed routine staining, IHC and molecular genetic testing [III, B].

Palliative interventions may be useful in case of local complications related to the primary tumour or metastatic foci which cannot be managed by conservative measures, e.g. lung abscess, empyema, massive haemoptysis, spinal cord compression and pathological bone fractures.

In the 8th edition of the tumour, node, metastasis (TNM) classification a new subcategory was introduced comprising patients with one metastasis in a single distant organ, defined as M1b disease, in contrast to patients with multiple metastases in one or more distant organs, currently M1c disease [289]. There is no general consensus on the precise definition of oligometastatic disease and clear evidence for surgical treatment is limited, as only relatively small prospective series are available [III, B] [290–292]. Prospective series suggest that complete surgical resection is necessary to obtain long-term survival and that mediastinal nodal involvement carries a poor prognosis [293]. This is further discussed in the section ‘Treatment of oligometastatic NSCLC’.

A specific subgroup consists of patients with malignant pleural nodules or malignant pleural effusion [293]. Extensive surgical procedures consisting of extrapleural pneumonectomy sometimes in combination with intraoperative ChT or hyperthermic ChT, have been described when extrathoracic metastases or mediastinal lymph node involvement have been excluded [294, 295]. However, these interventions carry a higher operative risk and prospective studies are currently not yet available [IV, D]. Persisting or recurrent pleural effusions are usually managed by pleurodesis to improve dyspnoea. Talc is the preferred agent and thoracoscopic poudrage may be better than injection of talc slurry in patients with primary lung cancer [II, B] [296, 297]. In case of a trapped lung by a thickened visceral pleural peel, indwelling pleural catheters or pleuroperitoneal shunts provide symptomatic relief [IV, B] [298, 299].

Lastly, salvage surgery may be considered in case of residual or progressive disease in the primary tumour or metastatic site when no other treatment options remain or specific complications occur, such as formation of a lung abscess in a necrotic cavity [300]. Long-term survival may be obtained in selected patients with limited distant involvement, but only case reports have been published so far [V, C] [301].

In a recent retrospective analysis of the National Cancer Database, a cohort of 300 572 patients with stage IIIA, IIIB or IV NSCLC were studied, of whom 4568 had a surgical intervention for stage IV disease [302]. A surgical selection score could be constructed comprising histology, tumour size, TNM status, Charlson comorbidity index, age, race,
Treatment of oligometastatic disease

The growing interest in oligometastases is based on the concept that long-term disease control, or even cure, may be achieved in some subgroups of these patients with aggressive local treatment of distant metastases (surgery or high-dose RT) [303]. The term ‘oligometastases’ refers to a limited number of distant metastases, although there is no consensus on the appropriate cut-off to define the oligometastatic state. Almost all published clinical trials investigating local treatment of oligometastatic disease have limited inclusion to patients with ≤5 metastases. In addition, the vast majority of the trials included patients with ≤3 metastases and in an individual patients meta-analysis published in 2014, almost 90% of the patients had a single metastasis [303]. Some studies also limited the number of organs in which these metastases are present [304]. It should be noted that many of these studies did not include PET-CT staging.

Oligometastases can be either synchronous, when a patient presents with a limited number of metastases at initial diagnosis, or metachronous when metastases are identified after treatment of the primary tumour [305]. The biology of synchronous and metachronous oligometastases may differ as illustrated by the fact that patients with metachronous presentation have a better prognosis [303]. In patients receiving systemic therapy (mainly in tumours with driver mutations treated with TKIs), the term oligoprogression can be also applied in the case of progression of a limited number of metastatic lesions, when all the other lesions remain stable. Clinical trials are ongoing in this setting.

In this heterogeneous group of patients with oligometastases, the specific approach to oligometastases in the brain has been discussed above. Another subgroup requiring further discussion is that of patients with a solitary lesion in the contralateral lung. The International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee carried out a systematic literature review, aiming at distinguishing a second primary from a metastasis in patients who have more than one pulmonary nodule [306]. This review concluded that few features are definitive, with many commonly used factors being suggestive, but carry a substantial risk of misclassification as the majority of second primary lung tumours are of the same histology. For these cases, the IASLC recommended a careful review by a multidisciplinary tumour board, and pursuit of radical therapy, such as that for a synchronous secondary primary tumour, when possible. Both surgery [307, 308] and SRS [309, 310] have been shown to result in long-term survivors in this setting [IV, B].

A systematic literature review identified 757 NSCLC patients treated with 1–5 (88% single metastases) synchronous or metachronous metastases [303]. These patients had a median age at diagnosis of 61 years, 98% had a good PS and two-thirds of patients had early-stage intrathoracic disease staged IA–IIB (after excluding metastatic disease). Surgery was the most common treatment modality for both primary (n=635, 83.9%) and metastases (n=339, 62.3%). Predictive factors for OS were synchronous versus metachronous metastases (P=0.001), N-stage (P=0.002) and adenocarcinoma histology (P=0.036). RPA for risk groups identified a good prognosis (low-risk) group presenting with metachronous metastases (5-year OS of 48%), an intermediate-risk group presenting with synchronous metastases and N0 disease (5-year OS of 36%) and, finally, a high-risk group presenting with synchronous metastases and intrathoracic N1/N2 disease (5-year OS of 14%). Caution is warranted before concluding that positive outcomes in these group of patients are due solely to the treatment intervention, rather than patient selection or other biases [305].

Stage IV patients with limited synchronous metastases at diagnosis may experience long-term disease-free survival (DFS) following systemic therapy and local consolidative therapy [LCT: high-dose RT including stereotactic ablative body RT (SABR) or surgery] [III, B]. Five phase II trials evaluating LCT in patients with NSCLC and synchronous oligometastases have been published. Three of these studies are small, single-arm studies which generally showed durable PFS in a subgroup of patients [290, 291, 311]. Two out of the five studies are randomised phase II studies that were stopped early after interim analysis. The first study randomised NSCLC patients between maintenance therapy (RT or surgery) in patients with ≤3 metastases, without progression after first-line systemic therapy (n=49). There was a significant difference in PFS time between the two groups (mPFS 11.9 months in the LCT group versus 3.9 months in the maintenance group; HR 0.35, P=0.005) [292]. The second study randomised patients with ≤5 metastatic sites between maintenance ChT alone versus SABR followed by maintenance ChT (n=29) [312]. So far, there are no published data on the impact of LCT on OS and long-term toxicity. Several clinical trials are ongoing to evaluate these important endpoints.

Stage IV patients with limited metachronous metastases may be treated with a local treatment as some may experience long-term DFS [IV, B]. However, this is based mainly on retrospective data. Although operative risk is low and long-term survival may be achieved, current evidence for surgery in oligometastatic disease is limited, and the relative contribution of surgery versus RT as local treatment modality has not yet been established. Solitary lesions in the contralateral lung should, in most cases, be considered as synchronous secondary primary tumours and, if possible, treated with curative-intent therapy [IV, B].

Similarly, there are few prospective data to support this treatment approach in patients with driver mutations who present with oligoprogression on molecular-targeted therapies [IV, C]. Furthermore, there is little data on the safety of combining SABR with molecularly targeted agents.

Some recommendations for the implementation of standard of care and advanced imaging modalities for identifying and following up patients with oligometastatic disease have been published by the European Organisation for Research
and Treatment of Cancer (EORTC) imaging group [313]. In the synchronous, metachronous and oligoprogressive setting, because of the limited evidence available, inclusion in clinical trials is preferred.

Focus on bone metastases

Given the incidence of bone metastases in NSCLC (30%–40% of patients with NSCLC develop bone metastases), it may be reasonable to evaluate for bone disease upon disease diagnosis. In general, the management aim is to palliate symptoms and prevent complications. Palliative RT is highly effective, usually with rapid pain relief. Both standard EBRT and SABR can be used to palliate painful, uncomplicated bone pain. However, the data on efficacy and safety of SABR are mainly from retrospective single institution studies. Systematic reviews of palliative RT trials for bone metastases showed that single and multiple fraction regimens provided equal pain relief; however, retreatment rates were significantly higher in patients receiving single fraction treatment [I, A] [314, 315].

Zoledronic acid reduces skeletal-related events (SREs) (pathological fracture, radiation/surgery to bone or spinal cord compression) [II, B] [316]. Denosumab shows a trend towards superiority to zoledronic acid in lung cancer in terms of SRE prevention [II, B] [317]. In an exploratory analysis of a large phase III trial, denosumab was associated with improved mOS in the subgroup of 702 metastatic NSCLC patients [318]. In the study of denosumab versus zoledronic acid in patients with advanced cancers, the time extent to which pain interfered with daily life (used as surrogate for QoL) was longer in patients treated with denosumab and with no pain or mild pain interference at baseline [319]. Both agents are associated with increased risk of osteonecrosis of the jaw. Zoledronic acid or denosumab are thus recommended in selected patients with advanced lung cancer with bone metastases [I, B]. Patients should be selected if they have a life expectancy of >3 months and are considered at high risk of SREs.

Role of minimally invasive procedures in stage IV NSCLC

Endoscopy has a role to play in palliative care, notably in case of symptomatic major airway obstruction or post-obstructive infection, where endoscopic debulking by laser, cryotherapy or stent placement may be helpful [III, C]. Endoscopy is useful in the diagnosis and treatment (endobronchial or by guiding endovascular embolisation) of haemoptysis [III, C]. Vascular stenting might be useful in NSCLC-related superior vena cava compression [III, B].

Role of palliative care in stage IV NSCLC

Early palliative care intervention is recommended, in parallel with standard oncological care [I, A], with evidence demonstrating that palliative care interventions significantly improve QoL. Two randomised trials evaluating the impact of introducing specialised palliative care early after diagnosis of stage IV disease on patient QoL in ambulatory patients were able to show improvements in QoL and mood, and, in one trial, a reduction in aggressive treatment and an improvement in mOS [320, 321].

Follow-up, long-term implications and survivorship

The optimal approach to post-treatment management of patients with NSCLC, including the role of radiological evaluation, is controversial, with very limited literature available. Due to the aggressive nature of this disease, generally close follow-up, at least every 6–12 weeks after first-line therapy, is advised to allow for early initiation of second-line therapy but should also depend on individual retreatment options [III, B].

Methodology

These Clinical Practice Guidelines were developed in accordance with the ESMO standard operating procedures for Clinical Practice Guidelines development, http://www.esmo.org/Guidelines/ESMOGuidelines-Methodology. The relevant literature has been selected by the expert authors. A summary of recommendations is provided in Table 4. A MCBS table with ESMO-MCBS scores is included in Table 5. ESMO-MCBS v1.1 was used to calculate scores for new therapies/indications approved by the EMA since 1 January 2016 [322]. Levels of evidence and grades of recommendation have been applied using the system shown in Table 6; some statements may be accompanied by a grade of recommendation alone. Statements without grading were considered justified standard clinical practice by the experts and the ESMO faculty.

Disclosure

DP has reported honoraria from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Merck Sharp and Dohme Oncology, Novartis, Pfizer, prIME Oncology, Roche; consulting, advisory role or lectures for AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck Sharp and Dohme Oncology, Novartis, Pfizer, prIME Oncology, Roche and has received travel grants from AstraZeneca, Roche, Novartis, prIME Oncology and Pfizer; SPo has reported honoraria from Pfizer, Boehringer Ingelheim, AstraZeneca, Roche, Lilly, Novartis, Takeda, Guardant Health, Bristol-Myers Squibb and consulting/advisory role for Boehringer Ingelheim, Roche, Lilly, Novartis, Pfizer and research funding from Boehringer Ingelheim, Epizyme, Bristol-Myers Squibb, Clovis Oncology, Roche, Lilly, Takeda; KMK has reported lecture fees and consultancy for AstraZeneca, AbbVie, Boehringer Ingelheim, Eli Lilly, Merck and Novartis; AV has reported honoraria from AstraZeneca, Roche and has received travel grants from AstraZeneca, Boehringer Ingelheim, Janssen-Cilag, Novartis and Novo Nordisk; DS has received travel grants from AstraZeneca, Celgene, Clovis Oncology, Genentech, Merck and Pfizer; JQ has reported honoraria from AstraZeneca and Genentech.
Ingelheim, Bristol-Myers Squibb, Lilly, Merck Sharpe & Dohme, Merck Serono, Novartis, Pfizer, Roche, Roche Diagnostics; SN has reported membership of the speaker bureau of Eli Lilly, Bristol-Myers Squibb, Merck Sharpe & Dohme, AstraZeneca, Boehringer Ingelheim, Roche, Incyte, Takeda; CFF has reported research/travel funding from AstraZeneca and Merck Sharpe & Dohme; TM has reported holding stock in Sanomics Ltd. And Hutchison Chi-Med, conducting research sponsored by AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis oncology, Merck Sharp and Dohme, Novartis, Pfizer, Roche, SFJ Pharmaceuticals and XCovery; has received speaker’s fee from AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck Sharp and Dohme, Novartis, BMS, Taiho, Takeda Oncology, prIME Oncology and Amoy Diagnostics Co, LTD and honoraria from AstraZeneca, Boehringer Ingelheim, Roche/Genentech, Pfizer, Eli Lilly, Merck Sorono, Merck Sharp and Dohme, Novartis, SFJ Pharmaceuticals, ACEA Biosciences Inc, Vertex Pharmaceuticals, Bristol-Myers Squibb, OncoGenex Technologies Inc, Celgene, Ignyta Inc, Cirina, Fishawack Facilitate Ltd, Janssen, Takeda, Hutchison Chi-Med, OrigiMed, Henfrui Therapeutics Inc, Sanofi-Aventis R&D and Yuhan Corporation for attending advisory boards; MH has reported honoraria for consultancy for Roche/Genentech, AstraZeneca, Merck, Bristol–Myers Squibb, Janssen, Mirati, Syndax, Shattuck Labs and has received research funding from Bristol-Myers Squibb; MR has reported honoraria for lectures and consultancy from AstraZeneca, Bristol-Myers Squibb, Celgene, Boehringer Ingelheim, Novartis, Abbvie, Pfizer, Merck Sharpe & Dohme, Merck, Roche, Lilly; SPE has reported educational grants, consultation, advisory boards and/or lectures for Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Eli Lilly, F. Hoffmann-La Roche, Janssen, Merck Sharp & Dohme, Novartis, Merck Serono, Pfizer, Regeneron and Takeda; PEVS has reported no conflicts of interest. ES has not reported any potential conflicts of interest.
References


96a. Gadgeel SM, Garassino MC, Esteban E et al. KEYNOTE-189: Updated OS and progression after the next line of therapy (BFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. J Clin Oncol 2019; 37(Suppl): v934.
98. Papadimitrakopoulou V, Cobo M, Bordon R et al. IMPOWER132: PFS and safety results with 1L atezolizumab + carboplatin/paclitaxel or carboplatin/pemetrexed in stage IV non-squamous NSCLC. IASLC World Conference on Lung Cancer 2018; abstr OA05.07.
101. Brahmer JR, Rodriguez-Abreu D, Robinson AG et al. Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. J Clin Oncol 2017; 35: 9000.


© European Society for Medical Oncology 2020. All rights reserved.


189. Nakamura A, Morita S, Hosomi Y et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GGP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). J Clin Oncol 2018; 36(Suppl): abstr 9005.


2029. Planchar D, Smit EF, Groen HJM et al. Updated survival of patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. J Clin Oncol 2017; 28(Suppl 5): 9075.


2030a. Planchar D, Besse B, Groen H. Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (mut) metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2020; 38(15_suppl): 9593.


## Table 1. A personalised medicine synopsis table for metastatic NSCLC

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Method</th>
<th>Use</th>
<th>LoE, GoR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EGFR mutation</strong></td>
<td>Any appropriate, validated method, subject to external quality assurance</td>
<td>To select those patients with <em>EGFR</em>-sensitising mutations most likely to respond to EGFR TKI therapy</td>
<td>I, A</td>
</tr>
<tr>
<td><strong>ALK rearrangement</strong></td>
<td>Any appropriate, validated method, subject to external quality assurance. FISH is the historical standard but IHC is now becoming the primary therapy-determining test, provided the method is validated against FISH or some other orthogonal test approach. NGS is an emerging technology.</td>
<td>To select those patients with <em>ALK</em> gene rearrangements most likely to respond to ALK TKI therapy</td>
<td>I, A</td>
</tr>
<tr>
<td><strong>ROS1 rearrangement</strong></td>
<td>FISH is the trial-validated standard. IHC may be used to select patients for confirmatory FISH testing but currently lacks specificity. NGS is an emerging technology. External quality assurance is essential.</td>
<td>To select those patients with <em>ROS1</em> gene rearrangements most likely to respond to ROS1 TKI therapy</td>
<td>II, A</td>
</tr>
<tr>
<td><strong>BRAF mutation</strong></td>
<td>Any appropriate, validated method, subject to external quality assurance</td>
<td>To select those patients with <em>BRAF</em> V600-sensitising mutations most likely to respond to BRAF inhibitor, with or without MEK inhibitor therapy</td>
<td>II, A</td>
</tr>
<tr>
<td><strong>NTRK rearrangement</strong></td>
<td>Screening by IHC or RNA NGS. A positive with the former requires confirmation by a molecular method (FISH, NGS). The latter should probably be validated by IHC.</td>
<td>To select those patients with <em>NTRK</em> gene rearrangements most likely to respond to NTRK TKI therapy</td>
<td>II, A</td>
</tr>
<tr>
<td><strong>PD-L1 expression</strong></td>
<td>IHC to identify PD-L1 expression at the appropriate level and on the appropriate cell population(s) as determined by the intended drug and line of therapy. Only specific</td>
<td>To enrich for those patients more likely to benefit from anti-PD-1 or anti-PD-L1 therapy. For pembrolizumab, testing is a companion diagnostic for nivolumab and</td>
<td>I, A</td>
</tr>
<tr>
<td>trial assays are validated. Internal and external quality assurance are essential</td>
<td>atezolizumab, testing is complementary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridisation; GoR, grade of recommendation; IHC, immunohistochemistry; LoE, level of evidence; MEK, mitogen-activated protein kinase; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; TKI, tyrosine kinase inhibitor.
Updated version published 15 September 2020 by the ESMO Guidelines Committee

Table 2. Clinical classification UICC TNM 8 [79]

<table>
<thead>
<tr>
<th>Primary tumour (T)</th>
<th>TX</th>
<th>Primary tumour cannot be assessed, or tumour proven by the presence of malignant cells in sputum or bronchial washings but not visualised by imaging or bronchoscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>T0</td>
<td>No evidence of primary tumour</td>
</tr>
<tr>
<td></td>
<td>Tis</td>
<td>Carcinoma in situ</td>
</tr>
<tr>
<td></td>
<td>T1</td>
<td>Tumour 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e. not in the main bronchus)</td>
</tr>
<tr>
<td></td>
<td>T1mi</td>
<td>Minimally invasive adenocarcinoma</td>
</tr>
<tr>
<td></td>
<td>T1a</td>
<td>Tumour 1 cm or less in greatest dimension</td>
</tr>
<tr>
<td></td>
<td>T1b</td>
<td>Tumour more than 1 cm but not more than 2 cm in greatest dimension</td>
</tr>
<tr>
<td></td>
<td>T1c</td>
<td>Tumour more than 2 cm but not more than 3 cm in greatest dimension</td>
</tr>
<tr>
<td></td>
<td>T2</td>
<td>Tumour more than 3 cm but not more than 5 cm; or tumour with any of the following features: - Involves main bronchus regardless of distance to the carina, but without involvement of the carina - Invades visceral pleura - Associated with atelectasis or obstructive pneumonitis that extends to the hilar region either involving part of or the entire lung</td>
</tr>
<tr>
<td></td>
<td>T2a</td>
<td>Tumour more than 3 cm but not more than 4 cm in greatest dimension</td>
</tr>
<tr>
<td></td>
<td>T2b</td>
<td>Tumour more than 4 cm but not more than 5 cm in greatest dimension</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>Tumour more than 5 cm but not more than 7 cm in greatest dimension or one that directly invades any of the following: parietal pleura, chest wall (including superior sulcus tumours) phrenic nerve, parietal pericardium; or separate tumour nodule(s) in the same lobe as the primary</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>Tumour more than 7 cm or of any size that invades any of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, carina; separate tumour nodule(s) in a different ipsilateral lobe to that of the primary</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Regional lymph nodes (N)</th>
<th>NX</th>
<th>Regional lymph nodes cannot be assessed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N0</td>
<td>No regional lymph node metastases</td>
</tr>
<tr>
<td></td>
<td>N1</td>
<td>Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension</td>
</tr>
<tr>
<td></td>
<td>N2</td>
<td>Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)</td>
</tr>
<tr>
<td></td>
<td>N3</td>
<td>Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Distant metastasis (M)</th>
<th>M0</th>
<th>No distant metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M1</td>
<td>Distant metastasis</td>
</tr>
<tr>
<td></td>
<td>M1a</td>
<td>Separate tumour nodule(s) in a contralateral lobe; tumour with pleural or pericardial nodules or malignant pleural or pericardial effusion</td>
</tr>
<tr>
<td></td>
<td>M1b</td>
<td>Single extrathoracic metastasis in a single organ</td>
</tr>
<tr>
<td></td>
<td>M1c</td>
<td>Multiple extrathoracic metastasis in a single or multiple organs</td>
</tr>
</tbody>
</table>

*aTis includes adenocarcinoma in situ and squamous carcinoma in situ.

The uncommon superficial spreading tumour of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.
Solitary adenocarcinoma (not more than 3 cm in greatest dimension), with a predominantly lepidic pattern and not more than 5 mm invasion in greatest dimension in any one focus.

T2 tumours with these features are classified T2a if 4 cm or less, or if size cannot be determined and T2b if greater than 4 cm but not larger than 5 cm.

Most pleural (pericardial) effusions with lung cancer are due to tumour. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumour, and the fluid is non-bloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion is not related to the tumour, the effusion should be excluded as a staging descriptor.

This includes involvement of a single non-regional node.

TNM, tumour, node and metastasis; UICC, Union for International Cancer Control.

Reprinted from [79] with permission from John Wiley & Sons, Inc.

Table 3. Staging and stage grouping UICC TNM 8 [79]

<table>
<thead>
<tr>
<th>Occult carcinoma</th>
<th>TX</th>
<th>N0</th>
<th>M0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0</td>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IA</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IA1</td>
<td>T1mi</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IA2</td>
<td>T1b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IA3</td>
<td>T1c</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IB</td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIA</td>
<td>T2b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIB</td>
<td>T1a-c T2a,b</td>
<td>N0, N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIA</td>
<td>T1a-c T2a,b</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>N0, N1</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIB</td>
<td>T1a-c T2a,b</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>N0, N1</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIC</td>
<td>T3, T4</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IV</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
<tr>
<td>Stage IVA</td>
<td>Any T</td>
<td>Any N</td>
<td>M1a, M1b</td>
</tr>
<tr>
<td>Stage IVB</td>
<td>Any T</td>
<td>Any N</td>
<td>M1c</td>
</tr>
</tbody>
</table>

TNM, tumour, node and metastasis; UICC, Union for International Cancer Control.

Reprinted from [79] with permission from John Wiley & Sons, Inc.
Table 4. Summary of recommendations

**Diagnosis**
- Bronchoscopy is a technique ideally suited to central lesions and can be used with bronchial washing, brushing, bronchial and transbronchial biopsy
- EBUS and/or EUS allows evaluation of regional lymph nodes
- Transthoracic fine needle aspiration and/or core biopsy, passing a needle through the parenchyma under imaging guidance (typically CT), is indicated in case of mid to peripheral lesions
- In presence of a pleural effusion, thoracentesis could represent both a diagnostic tool and a palliative treatment
- More invasive, surgical approaches (mediastinoscopy, mediastinotomy, thoracoscopy etc.) in the diagnostic workup can be considered when the previously described techniques cannot allow for an accurate diagnosis
- With systematic collaboration and constant communication between pathologists and procedure performers, diagnostic yields will be significantly greater than with blind biopsies

**Pathology/molecular biology**
- Adequate tissue material for histological diagnosis and molecular testing should be obtained to allow for individual treatment decisions
- Pathological diagnosis should be made according to the 2015 WHO classification of lung tumours
- Specific subtyping of all NSCLCs is necessary for therapeutic decision making and should be carried out wherever possible. IHC stains should be used to reduce the NSCLC-NOS rate to fewer than 10% of cases diagnosed [IV, A]
- *EGFR* mutation status should be systematically analysed in advanced NSCC [I, A]. Test methodology should have adequate coverage of mutations in exons 18–21, including those associated with resistance to some therapies [III, B]. At a minimum, when resources or material are limited, the most common activating mutations (exon 19 deletion, exon 21 *L858R* point mutation) should be determined [I, A]
- The availability of TKIs effective against *T790M*-mutant recurrent disease makes *T790M* testing on disease relapse mandatory [I, A]
- All patients with a negative cfDNA blood test still require tissue biopsy [II, A]
- Testing for *ALK* rearrangement should be systematically carried out in advanced non-squamous NSCLC [I, A]
- Detection of the *ALK* translocation by FISH remains a standard, but IHC with high-performance ALK antibodies and validated assays may be used for screening [III, A] and have recently been accepted as an equivalent alternative to FISH for ALK testing
- Testing for *ROS1* rearrangement should be systematically carried out in advanced NSCLC [III, A]. Detection of the *ROS1* translocation by FISH remains a standard; IHC may be used as a screening approach [IV, A]
- *BRAF V600* mutation status should be systematically analysed in advanced NSCLC for the prescription of BRAF/MEK inhibitors [II, A]
- Screening for *ROS1* rearrangements may use IHC or NGS, with appropriate testing follow-up to validate a positive result [IV, A]
- Molecular *EGFR* and *ALK* testing are not recommended in patients with a confident diagnosis of SCC, except in unusual cases, e.g. never/former light smokers or long-time ex-smokers [IV, A]
- If available, multiplex platforms (NGS) for molecular testing are preferable [III, A]. Whatever testing modality is used, it is mandatory that adequate internal validation and quality control measures are in place and that laboratories participate in, and perform adequately in, external quality assurance schemes for each biomarker test [III, A]
- *PD-L1* IHC should be systematically determined in advanced NSCLC [I, A]
- Testing is required for pembrolizumab therapy but may also be informative when nivolumab or atezolizumab are used [I, A]

**Staging and risk assessment**
- A complete history including a precise smoking history and comorbidities, weight loss, PS and physical examination must be recorded
- Laboratory: standard tests including routine haematology, renal and hepatic functions and bone biochemistry tests are required
- Routine use of serum tumour markers, such as CEA, is not recommended [IV, B]
- Contrast-enhanced CT scan of the chest and upper abdomen including the liver and the adrenal glands should be carried out at diagnosis
Management of advanced/metastatic disease

- The treatment strategy should consider the histology, molecular pathology, age, PS, comorbidities and the patient’s preferences.
- Systemic therapy should be offered to all stage IV patients with PS 0–2 [I, A].
- In any stage of NSCLC, smoking cessation should be highly encouraged, because it improves the outcome [II, A].

First-line treatment of EGFR- and ALK-negative NSCLC, PD-L1 ≥50%

- Pembrolizumab is considered a standard first-line option for patients with advanced NSCLC and PD-L1 expression ≥ 50% who do not have contraindications to use of immunotherapy [I, A; ESMO-MCBS v1.1 score: 5].
- Atezolizumab represents a promising first-line treatment option in patients with PD-L1-high NSCLC [I, B; not EMA-approved].

First-line treatment of NSCLC without actionable oncogenic driver regardless of PD-L1 status

- ChT with platinum doublets should be considered in all stage IV NSCLC patients without an actionable oncogenic driver, without major comorbidities and PS 0–2 [I, A].
- Platinum-based doublets are the recommended ChT option in all stage IV NSCLC patients with no contraindications to platinum compounds [I, A].
- Four cycles of platinum-based doublets followed by less toxic maintenance monotherapy [I, A], or 4 cycles in patients not suitable for maintenance monotherapy [I, A], up to a maximum of 6 [IV, B], is currently recommended.
- The carboplatin/nab-P regimen could be considered a chemotherapeutic option in advanced NSCLC patients, particularly in patients with greater risk of neurotoxicity, pre-existing hypersensitivity to paclitaxel or contraindications for standard paclitaxel premedication [I, B].
- Combinations of platinum-based ChT and anti-PD-(L1) inhibitors have reproducibly demonstrated superiority to standard platinum-based ChT. In the absence of contraindications and conditioned by the registration and accessibility of anti-PD-(L1) combinations with platinum-based ChT, this strategy will be preferred to platinum-based ChT in patients with PS 0-1 and PD-L1 < 50%.
- Nivolumab plus ipilimumab represents an optional treatment regimen for patients with NSCLC [I, A; not EMA-approved].

First-line treatment of SCC

- Platinum-based doublets with a third-generation cytotoxic agent (gemcitabine, vinorelbine, taxanes) are recommended in advanced SCC patients without major comorbidities and PS 0–2 [I, A].
- The addition of necitumumab to cisplatin/gemcitabine has not been adopted as a standard in Europe for advanced SCC and its use should be carefully evaluated [I, C; ESMO-MCBS v1.1 score: 1].
• Combination of pembrolizumab and carboplatin with paclitaxel or nab-P is a standard choice in patients with metastatic squamous NSCLC [I, A; ESMO-MCBS v1.1 score: 4]
• The use of atezolizumab with carboplatin and nab-P represents an option in patients with metastatic squamous NSCLC [I, B; not EMA-approved]
• Other combinations of platinum-based ChT and anti-PD-(L1) inhibitors will demonstrate superiority to standard platinum-based ChT. In the absence of contraindications and conditioned by the registration and accessibility of anti-PD-(L1) combinations with platinum-based ChT, this strategy should be preferred to platinum-based ChT in patients with PS 0-1 and PD-L1 < 50%
• Nivolumab plus ipilimumab represents an optional treatment regimen for patients with SCC [I, A; not EMA-approved]

First-line treatment of NSCC

• Pemetrexed-based combination ChT is preferred to gemcitabine- or docetaxel-based combinations in patients with non-squamous tumours [II, A]
• Pemetrexed use is restricted to NSCC in any line of treatment in advanced disease [II, A]
• The combination of carboplatin with pemetrexed can be an option in patients with a contraindication to cisplatin [II, B]
• Pemetrexed in combination with pemetrexed and a platinum-based ChT should be considered a standard option in metastatic non-squamous NSCLC [I, A; ESMO-MCBS v1.1 score: 4]
• Atezolizumab in combination with pemetrexed and a platinum-based ChT is a therapeutic option in metastatic non-squamous NSCLC [I, B; not EMA-approved]
• Combination of atezolizumab and bevacizumab with carboplatin and paclitaxel is a therapeutic option in patients with PS 0-1 with metastatic non-squamous NSCLC, in the absence of contraindications to use of immunotherapy [I, A; ESMO-MCBS v1.1 score: 3], and more specifically [III, A; ESMO-MCBS v1.1 score: 3] for EGFR
• Combination of atezolizumab and carboplatin/nab-P followed by maintenance atezolizumab represents a new standard treatment opportunity [I, A; ESMO-MCBS v1.1 score: 3]
• Other combinations of platinum-based ChT and anti-PD-(L1) inhibitors will demonstrate superiority to standard platinum-based ChT. In the absence of contraindications and conditioned by the registration and accessibility of anti-PD-(L1) combinations with platinum-based ChT, this strategy should be preferred to platinum-based ChT in patients with PS 0-1 and PD-L1 < 50%
• Nivolumab plus ipilimumab represents an optional treatment regimen for patients with NSCC [I, A; not EMA-approved]
• If PD-(L)1 is not available for ChT combinations, bevacizumab combined with paclitaxel/carboplatin may be offered in the absence of contraindications in patients with advanced NSCC and PS 0-1 (bevacizumab should be given until progression) [I, A]
• Bevacizumab might be considered with platinum-based regimens beyond paclitaxel/carboplatin in absence of contraindications [II, B]

Maintenance

• Maintenance ChT should be offered only to patients with PS 0–1 after first-line ChT. Decisions about maintenance should consider histology, response to platinum-doublet ChT and remaining toxicity after first-line ChT, PS and patient’s preference
• In patients with NSCC and PS 0–1, pemetrexed switch maintenance should be considered in patients having disease control following 4 cycles of non-pemetrexed-containing platinum-based ChT [II, B]
• Pemetrexed continuation maintenance should be considered in patients having disease control following 4 cycles of cisplatin/pemetrexed [I, A]
• Continuation maintenance with gemcitabine is an option in NSCLC patients treated with 4 cycles of cisplatin/gemcitabine [I, C]
• Maintenance treatment with erlotinib is only recommended for NSCC patients with an EGFR-sensitising mutation [III, B]

PS 2 and beyond

• ChT prolongs survival and improves QoL in NSCLC patients with PS 2 when compared with BSC [I, A]
• Platinum-based (preferably carboplatin) combination ChT should be considered in eligible PS 2 patients [I, A]
• Single-agent ChT with gemcitabine, vinorelbine, docetaxel [I, B] or pemetrexed (restricted to NSCC) [II, B] is an...
alternative treatment option. The use of checkpoint inhibitors for patients with advanced NSCLC and PS 2 can be considered [III, B]

- Poor PS (3–4) patients should be treated with BSC only in the absence of molecularly targetable alterations, such as EGFR mutations, ALK or ROS1 rearrangements or BRAF V600 mutation [III, B]

**Elderly patients**

- Immunotherapy should be considered according to standard recommendations in elderly patients [III, A]
- Carboplatin-based doublet ChT is recommended in eligible elderly patients with PS 0–2 and with adequate organ function [I, A]
- For those patients not eligible for doublet ChT, single-agent ChT remains the standard of care [I, B]

**Second-line treatment of NSCLC without actionable oncogenic driver**

- Patients clinically or radiologically progressing after first-line therapy with PS 0–2 should be offered second-line therapy irrespective of administration of maintenance treatment [I, A]
- In patients with progression after first-line immunotherapy with pembrolizumab, platinum-based ChT is recommended as second-line treatment option [V, B]
- There is a general trend across each of the phase III studies in second-line (nivolumab, pembrolizumab and atezolizumab versus docetaxel) for enriched efficacy of anti-PD-1/PD-L1 agents in patients with higher PD-L1 expression compared with those with no/less PD-L1 expression. However, unselected patients may still have improved survival and tolerability with anti-PD-1/PD-L1 agents compared with docetaxel [I, A]
- PD-L1 and PD-1 inhibitors (nivolumab, pembrolizumab and atezolizumab) are the treatment of choice for most patients with advanced, previously treated, PD-L1-naïve NSCLC, irrespective of PD-L1 expression [I, A]
- Nivolumab is recommended in both squamous [I, A; ESMO-MCBS v1.1 score: 5] and non-squamous NSCLC [I, A; ESMO-MCBS v1.1 score: 5]
- Pembrolizumab is recommended in patients with previously treated NSCLC with PD-L1 expression > 1% [I, A; ESMO-MCBS v1.1 score: 5]
- Atezolizumab is recommended in patients with advanced NSCLC previously treated with one or two prior lines of ChT [I, A; ESMO-MCBS v1.1 score: 5]
- In patients not suitable for immunotherapy, second-line ChT is recommended. Comparable options as second-line therapy consist of pemtrexed, for NSCC only, or docetaxel, with a more favourable tolerability profile for pemtrexed [I, B]
- Treatment may be prolonged if disease is controlled and toxicity acceptable [II, B]
- Nintedanib/docetaxel is a treatment option in patients with adenocarcinoma progressing after previous ChT or immunotherapy [II, B]
- Ramucirumab/docetaxel is a treatment option in patients with NSCLC progressing after first-line ChT or immunotherapy with PS 0–2 [I, B]
- Combination of paclitaxel and bevacizumab is another treatment option [I, C] but it is not EMA-approved
- Erlotinib represents a potential second/third-line treatment option in particular for patients not suitable for immunotherapy or second-line ChT in unknown EGFR status or EGFR WT tumours [II, C]
- In patients with advanced SCC with PS 0–2 unfit for ChT or immunotherapy, afatinib is a potential option with unknown EGFR status or EGFR WT patients [I, C; ESMO-MCBS v1.1 score: 2]

**First-line treatment of EGFR-mutated NSCLC**

- Patients with a tumour with a sensitising EGFR mutation should receive first-line EGFR TKIs including erlotinib, gefitinib or afatinib [I, A], or dacomitinib [I, B; ESMO-MCBS v1.1 score: 3]. None of the four EGFR TKIs is consensually considered as a preferred option [IV, C]
- First-line osimertinib is now considered as preferred option in first line for patients with a tumour with sensitising EGFR mutations [I, A; MCBS v1.1 score: 4]
- All patients should be considered for EGFR TKIs irrespective of clinical parameters, including PS, gender, tobacco exposure, histology and line of therapy [I, A]
- Erlotinib/bevacizumab represents a front-line treatment option in patients with EGFR-mutated tumours [II, B; ESMO-MCBS v1.1 score: 3]
- Ramucirumab with erlotinib is associated with longer PFS compared with erlotinib and placebo at the first interim analysis but data are still immature [I, B; ESMO-MCBS v1.1 score: 3]
- Addition of carboplatin and pemetrexed to gefitinib represents a first-line option in patients with EGFR-mutated tumours [I, B; not EMA-approved]
- Patients who have radiological progression with ongoing clinical benefit may continue with EGFR TKI [II, A]
- In EGFR-mutated NSCLC patients with localised distant progression and ongoing systemic control, continuation of treatment with EGFR TKI in combination with local treatment of progressing metastatic sites may be considered [III, B]

### Second-line treatment of EGFR-mutated NSCLC
- EGFR TKI should be stopped at the time when patient starts ChT for treatment of TKI resistance [I, A]
- All tumours with clinical evidence of EGFR TKI resistance, not previously treated with osimertinib, should be tested for presence of EGFR exon 20 T790M mutation [I, A]
- Liquid biopsy can be used as the initial test for detection of T790M mutation, and if tested negative, re-biopsy should be attempted if feasible [II, A]
- Osimertinib is the standard therapy for patients whose tumours are tested positive for T790M either in liquid biopsy or re-biopsy, if not received previously [I, A; ESMO-MCBS v1.1 score: 4]
- In EGFR-mutated NSCLC with CNS disease, osimertinib is highly active
- Platinum-based doublet is the standard therapy for patients whose tumour is tested positive T790M negative in either re-biopsy or in liquid biopsy (only when re-biopsy is not feasible) [I, A]
- Combination of atezolizumab and bevacizumab with carboplatin and paclitaxel should be considered as a therapeutic option in patients with EGFR-mutated tumour, PS 0–1, in absence of contraindications to use of immunotherapy after targeted therapies have been exploited [III, A; not EMA-approved]

### First-line treatment of ALK-rearranged NSCLC
- Patients with ALK-rearranged NSCLC should receive first-line ALK TKI including crizotinib [I, A; ESMO-MCBS v1.1 score: 4], ceritinib [I, B; ESMO-MCBS v1.1 score: 4], alectinib [I, A] or brigatinib [I, B; not EMA-approved]
- Alectinib is associated with longer PFS and lower toxicity than crizotinib and showed activity against CNS disease in patients previously untreated with ALK-positive NSCLC [I, A]
- Brigatinib is associated with longer PFS than crizotinib at the second interim analysis and showed activity against CNS disease in previously untreated patients with ALK-positive NSCLC [I, B; not EMA-approved]
- In patients with CNS involvement, front-line use of ALK TKIs is effective, and alectinib [III, A], brigatinib [III, B] or ceritinib [IV, B] is recommended. Ceritinib represents a better treatment strategy than ChT [I, B] and presumably crizotinib [IV, B]; alectinib represents a better treatment option than crizotinib [I, A]; brigatinib represents a better treatment option than crizotinib [I, B; not EMA-approved]
- Ensartinib has shown an improvement in PFS compared with frontline crizotinib [I, A; not EMA-approved]
- In ALK-rearranged NSCLC patients with localised distant progression and ongoing systemic control, continuation of treatment with ALK TKI in combination with local treatment of progressing metastatic sites may be considered [III, B]

### Second and further lines of treatment of ALK-rearranged NSCLC
- Any patient with NSCLC harbouring an ALK fusion should receive a new generation ALK TKI as next-line therapy, if not received previously [I, A]
- Ceritinib and alectinib are recommended in patients with ALK-positive advanced NSCLC who progress on treatment with or are intolerant to crizotinib [I, A; ESMO-MCBS v1.1 score: 4]
- Brigatinib represents an additional treatment option at crizotinib resistance [III, A; ESMO-MCBS v1.1 score: 3]
- Lorlatinib shows efficacy among patients with ALK mutations at crizotinib resistance [III, A; ESMO-MCBS v1.1 score: 3]
- In patients with ALK-positive NSCLC progressing on crizotinib with CNS progression, treatment should be a next-generation ALK TKIs [II, A]
- Ensartinib possesses a high activity against a broad range of known crizotinib-resistant ALK mutations and CNS metastases
- In patients who progress after a second-generation ALK TKI, the next-generation ALK inhibitor lorlatinib is an option if available [III, A; ESMO-MCBS v1.1 score: 3]

### Treatment of ROS1-rearranged NSCLC
- Crizotinib is recommended in the first-line setting in patients with stage IV NSCLC with ROS1 rearrangement [III, A; ESMO-MCBS v1.1 score: 3]
- In patients with ROS1-positive NSCLC, who have not received crizotinib in the first-line setting, single-agent crizotinib may be offered as second-line therapy [III, A]
<table>
<thead>
<tr>
<th>Brain metastases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Role of RT in stage IV</td>
</tr>
<tr>
<td>- EBRT is indicated in cases of haemoptysis and symptomatic airway obstruction [III, B]</td>
</tr>
<tr>
<td>- RT can achieve symptom control for a variety of clinical scenarios including haemoptysis, symptomatic airway obstruction, painful chest wall disease and bone metastasis, superior vena cava syndrome, soft tissue or neural invasion [II, B]</td>
</tr>
<tr>
<td>- Administration of high-dose RT does not result in greater levels of palliation [II, B]</td>
</tr>
<tr>
<td>- EBRT alone is more effective for palliation than EBB alone [II, B]</td>
</tr>
<tr>
<td>- For patients previously treated by EBRT who are symptomatic from recurrent endobronchial central obstruction, EBB may be considered in selected cases [III, C]</td>
</tr>
<tr>
<td>- Neurological symptoms from spinal cord compression can be relieved by early RT [II, B]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients with NSCLC with other actionable oncogenic driver</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Larotrectinib is the first tumour-agnostic drug to be approved in the European Union [II, B; ESMO-MCBS v1.1 score: 3] and is recommended in NTRK gene fusion patients with advanced NSCLC who were previously treated [II, B]</td>
</tr>
<tr>
<td>- Targeting RET (while evidence of benefit is stronger) is not currently routinely recommended and recruitment into open trials is encouraged [II, B]</td>
</tr>
<tr>
<td>- Selpercatinib (LOXO-292) and pralsetinib (BLU-667) showed preliminary strong efficacy in RET-fusion NSCLC [III, B]</td>
</tr>
<tr>
<td>- Targeting MET amplification is not currently routinely recommended and recruitment into open trials is encouraged [III, C]</td>
</tr>
<tr>
<td>- Targeting METex14 variants (while evidence of benefit is stronger) is not currently routinely recommended and recruitment into open trials is encouraged [III, C]</td>
</tr>
<tr>
<td>- Capmatinib and tepotinib have demonstrated clinically meaning efficacy in NSCLC patients harbouring METex14 mutations [III, B]</td>
</tr>
<tr>
<td>- Trastuzumab deruxtecan is a novel antibody-drug conjugate whose use is mainly restricted to clinical trials, while activity is promising [III, B]</td>
</tr>
<tr>
<td>- Entrectinib is EMA-approved for the treatment of solid tumours expressing NTRK gene fusions [III, B; ESMO-MCBS v1.1 score: 3]</td>
</tr>
<tr>
<td>- Larotrectinib is the first tumour-agnostic drug to be approved in the European Union for the treatment of adult and paediatric patients with solid tumours that display a NTRK gene fusion [III, B; ESMO-MCBS v1.1 score: 3]</td>
</tr>
<tr>
<td>- Given the paucity of robust data, targeting HER2 dysregulation is not currently recommended and recruitment into open trials is encouraged [III, C]</td>
</tr>
<tr>
<td>- KRAS(G12C)-mutant recruitment into open trials is encouraged [III, C].</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment of BRAF-mutated NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Patients with stage IV NSCLC with BRAF V600 mutation should be exposed in first or second line to BRAF/MEK inhibition using dabrafenib/trametinib [III, A; ESMO-MCBS v1.1 score: 2]</td>
</tr>
<tr>
<td>- If patients have received BRAF/MEK inhibition in the first-line setting, then they may be offered platinum-based ChT in the second-line setting [IV, A]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Role of RT in stage IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>- EBRT should not be offered in RPA class III patients in view of the dismal prognosis [I, A]; only BSC is recommended</td>
</tr>
<tr>
<td>- The most frequent WBRT schedules are 20 Gy in 5 fractions or 30 Gy in 10 fractions, with no difference in outcome [I, A]</td>
</tr>
</tbody>
</table>
- For most patients with symptomatic brain metastases and/or significant oedema, dexamethasone or equivalent corticosteroid is recommended [III, A]
- Neuroprotective agents are not recommended for routine use [II, C]
- Hippocampus avoidance WBRT is not currently recommended as a standard treatment [III, C]
- In case of single brain metastases surgical resection can be considered [III, B]
- Postoperative WBRT or SRS is recommended after surgical resection [I, A]
- In the case of a limited number of metastases, SRS alone is the recommended treatment in patients with RPA class I–II [III, B]
- SRS alone, without WBRT but with close MRI brain imaging follow-up, is an alternative strategy [III, B]
- The indication for SRS is based on total tumour volume rather than numbers of metastases, as the risk of radionecrosis increases with tumour volume [III, C]
- In patients with asymptomatically detected CNS metastases at presentation, systemic therapy with deferred RT should be considered due to similar intracranial and extracranial response [II, B]
- In patients with an actionable oncogenic driver (e.g. EGFR, ALK) and clinically asymptomatic brain metastases, next-generation TKIs may restore control of brain disease and delay cranial RT [II, A]
- There is currently limited trial data demonstrating safety and efficacy of immunotherapy in patients with small-volume untreated CNS metastases [III, B]

**LM carcinomatosis**

- A high index of suspicion should be borne for LM involvement especially in patients with actionable oncogenic drivers having TKI treatment [V]. CSF sampling is diagnostic of LMD but limited by low sensitivity, albeit with high specificity [IV, A]
- Patients with actionable oncogenic drivers and LMD can be treated with CNS-penetrant next-generation TKIs [III, B]
- ChT and bevacizumab may have activity both extracranially and intracranially, and also in the context of LMD [IV, C]
- Intra-CSF pharmacotherapy can be considered contingent on clinical factors [V, C]
- In exceptional cases, focal RT can be considered for circumscribed, notably symptomatic, lesions [V, C]

**Surgery in stage IV**

- Surgery may be indicated for diagnosis, evaluation of response to systemic therapy and palliation
- Highly selected patients may be considered for lung resection with therapeutic intent or even for a salvage procedure [IV, C]
- When metastatic disease is suspected on PET scanning, invasive surgical procedures such as incisional biopsies, mediastinoscopy, thoracoscopy (VATS) or laparoscopy may be required to obtain relevant biopsy samples. Adequate samples should be provided to the pathologist for detailed routine staining, IHC and molecular genetic testing [III, B]
- Persisting or recurrent pleural effusions are usually managed by pleurodesis to improve dyspnoea. Talc is the preferred agent and thorascopoc poudrage may be better than injection of talc slurry in patients with primary lung cancer [II, B]
- In case of a trapped lung by a thickened visceral pleural peel, indwelling pleural catheters or pleuroperitoneal shunts provide symptomatic relief [IV, B]

**Treatment of oligometastatic disease**

- Stage IV patients with one to three synchronous metastases at diagnosis may experience long-term DFS following systemic therapy and local consolidative therapy (high-dose RT or surgery) [III, B]. Because of the limited evidence, these patients should be discussed within a multidisciplinary tumour board [II, B], and inclusion in clinical trials is preferred
- Although operative risk is low and long-term survival may be achieved, current evidence for surgery in oligometastatic disease is limited, and the relative contribution of surgery versus RT as local treatment modality has not been established yet
- Stage IV patients with limited metachronous metastases may be treated with a radical local therapy (high-dose RT or surgery) and may experience long-term DFS [IV, B]. However, this is based mainly on retrospective data and inclusion in clinical trials is preferred
• Stage IV patients with driver mutations, with oligoprogession while on molecular-targeted therapy, may be treated with a radical local treatment (high-dose RT or surgery) and may experience long-term DFS [IV, C]. However, this is based mainly on retrospective data and inclusion in clinical trials is preferred.

• Solitary lesions in the contralateral lung should, in most cases, be considered as synchronous secondary primary tumours and, if possible, treated with curative-intent therapy [IV, B]

**Bone metastases**

• Zoledronic acid reduces SREs (pathological fracture, radiation/surgery to bone or spinal cord compression) [II, B] and is recommended in stage IV bone metastatic disease [I, B]

• Denosumab shows a trend towards superiority to zoledronic acid in lung cancer in terms of SRE prevention [II, B] and is recommended in selected patients with advanced lung cancer with bone metastases [I, B]

• In the case of uncomplicated painful bone metastases, single fraction EBRT is the recommended treatment on the basis of non-inferiority to multiple fraction RT [I, A]

**Role of minimally invasive procedures in stage IV NSCLC**

• In case of symptomatic major airways obstruction or post-obstructive infection, endoscopy debulking by laser, cryotherapy or stent placement may be helpful [III, C]

• Endoscopy is useful in the diagnosis and treatment (endobronchial or by guiding endovascular embolisation) of haemoptysis [III, C]

• Vascular stenting might be useful in NSCLC-related superior vena cava compression [III, B]

**Palliative care in stage IV NSCLC**

• Early palliative care intervention is recommended, in parallel with standard oncological care [I, A]

**Follow-up**

• Close follow-up, at least every 6–12 weeks after first-line therapy, is advised to allow for early initiation of second-line therapy but should depend on individual retreatment options [III, B]
Table 5. ESMO-MCBS table for new therapies/indications in NSCLCa

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Disease setting</th>
<th>Trial</th>
<th>Control</th>
<th>Absolute survival gain</th>
<th>HR (95% CI)</th>
<th>QoL/toxicity</th>
<th>ESMO-MCBS scoreb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afatinib, an irreversible ErbB family blocker</td>
<td>Advanced</td>
<td>Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase III trial [168, 169] Phase III NCT01523587</td>
<td>Erlotinib, as second-line treatment of patients with advanced SCC of the lung Control median OS: 6.8 months</td>
<td>OS gain: 1.1 months</td>
<td>OS HR: for death 0.81 (0.69–0.95)</td>
<td>Similar toxicity profile Improved overall health-related QoL</td>
<td>2 (Form 2a)</td>
</tr>
<tr>
<td>Alectinib, potent ALK tyrosine kinase inhibitor</td>
<td>Advanced</td>
<td>Alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer: results from the phase III (ALUR study) [207] Phase III NCT02604342</td>
<td>ChT (pemetrexed or docetaxel) in previously treated ALK-rearranged patients Control PFS (investigator assessment): 1.4 months</td>
<td>PFS gain: 8.2 months</td>
<td>PFS HR: 0.15 (0.08–0.29)</td>
<td>Improved toxicity profile</td>
<td>4 (Form 2b)</td>
</tr>
<tr>
<td>Alectinib, potent ALK tyrosine kinase inhibitor</td>
<td>Advanced</td>
<td>Alectinib versus crizotinib in untreated ALK-positive NSCLC (J-ALEX) [202] Phase III NCT02075840</td>
<td>Crizotinib in untreated, ALK-rearranged patients Control PFS, independent review committee-assessed: 10.4 months</td>
<td>Estimated based on UL PFS gain: 8.7 months</td>
<td>PFS (independent review committee-assessed) HR: 0.34 (0.21–0.54)</td>
<td>Improved toxicity profile</td>
<td>4 (Form 2b)</td>
</tr>
<tr>
<td>Atezolizumab, humanised engineered IgG1 monoclonal</td>
<td>Advanced</td>
<td>Atezolizumab versus docetaxel in patients with previously treated NSCLC (OAK): a phase III, open-label, multicentre</td>
<td>Docetaxel in squamous or non-squamous patients stage IIIIB or IV who had</td>
<td>OS gain: 4.2 months</td>
<td>OS HR: 0.73 (0.62–0.87)</td>
<td>Improved toxicity profile</td>
<td>5 (Form 2a)</td>
</tr>
</tbody>
</table>

© European Society for Medical Oncology 2020. All rights reserved.
<table>
<thead>
<tr>
<th>Antibody targeting PD-L1</th>
<th>Randomised controlled trial</th>
<th>Received one to two previous cytotoxic ChT regimens</th>
<th>Control OS: 9.6 months</th>
<th>OS gain: 4.5 months</th>
<th>PFS HR: 0.78 (0.64–0.96)</th>
<th>Similar toxicity</th>
<th>3 (Form 2a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atezolizumab with combination chemotherapy and bevacizumab WT population per primary endpoint</td>
<td>Atezolizumab for first-line treatment of metastatic non-squamous NSCLC [97]</td>
<td>Bevacizumab, paclitaxel and carboplatin</td>
<td>Control PFS: 6.8 months</td>
<td>Control OS: 14.7 months</td>
<td>PFS HR: 0.62 (0.52–0.74)</td>
<td>Similar toxicity</td>
<td>3 (Form 2a)</td>
</tr>
<tr>
<td>Atezolizumab with combination chemotherapy and bevacizumab in EGFR mutation</td>
<td>Atezolizumab for first-line treatment of metastatic non-squamous NSCLC [97a]</td>
<td>Bevacizumab, paclitaxel and carboplatin</td>
<td>Control PFS: 6.1 months</td>
<td>PFS gain: 3.1 months</td>
<td>PFS HR: 0.59 (0.37–0.94)</td>
<td>Similar toxicity</td>
<td>3 (Form 2b)</td>
</tr>
<tr>
<td>Atezolizumab in combination with carboplatin and nab-paclitaxel</td>
<td>Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial [98a]</td>
<td>Carboplatin plus nab-paclitaxel</td>
<td>Control PFS: 5.5 months</td>
<td>Control OS: 13.9 months</td>
<td>PFS gain: 1.5 months</td>
<td>PFS HR: 0.64 (0.54–0.77)</td>
<td>3 (Form 2a)</td>
</tr>
<tr>
<td>Bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination with erlotinib</td>
<td>Advanced</td>
<td>Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous NSCLC harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase II study [190] Phase II Japan Pharmaceutical Information Center, number Japic CTI-111390</td>
<td>Erlotinib alone as a first-line therapy until disease progression or unacceptable toxicity Control median PFS: 9.7 months</td>
<td>PFS gain: 6.3 months</td>
<td>PFS HR: 0.54 (0.36–0.79)</td>
<td>Deteriorated toxicity profile not reaching the toxicity thresholds for penalty No improvement in QoL</td>
<td>3 (Form 2b)</td>
</tr>
</tbody>
</table>

| Brigatinib | Advanced | Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase–positive non–small-cell lung cancer: a randomized, multicenter phase II trial [209a] Phase II NCT02737501 | Single arm mPFS (180 mg): 12.9 months ORR: 54% mDoR: 11.1 months PFS: 12.0 months | | | Tolerable toxicity | 3 (Form 3) |

| Ceritinib, potent and selective oral tyrosine kinase inhibitor of ALK | Advanced | Ceritinib versus chemotherapy in patients with ALK-rearranged NSCLC previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase III trial [206] Phase III NCT01828112 | ChT, pemetrexed or docetaxel (investigator choice), in patients with ALK-rearranged stage IIIB or IV Control PFS: 1.6 months | PFS gain: 3.8 months | PFS HR: 0.49 (0.36–0.67) | Similar treatment related serious adverse events Improved overall health-related QoL | 4 (Form 2b) |

<p>| Ceritinib, potent and selective oral tyrosine kinase inhibitor of ALK | Advanced | First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged NSCLC (ASCEND-4): a Platinum-based ChT in untreated patients stage IIIB/IV ALK-rearranged non- | | PFS gain: 8.5 months | PFS HR: 0.55 (0.42–0.73) | Delayed deterioration in overall health-related QoL | 4 (Form 2b) |</p>
<table>
<thead>
<tr>
<th><strong>Crizotinib, a small-molecule tyrosine kinase inhibitor of ALK, ROS1 and MET</strong></th>
<th><strong>Advanced</strong></th>
<th><strong>First-line crizotinib versus chemotherapy in ALK-positive lung cancer [199]</strong></th>
<th><strong>Pemetrexed plus platinum ChT Control PFS: 7.0 months</strong></th>
<th><strong>PFS gain: 3.9 months</strong></th>
<th><strong>PFS HR: 0.45 (0.35–0.60)</strong></th>
<th><strong>Improved QoL</strong></th>
<th><strong>4 (Form 2b)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crizotinib in ROS1-rearranged NSCLC [216]</strong></td>
<td><strong>Advanced</strong></td>
<td><strong>Cohort study: 50 patients (86% had received at least one previous line) (no control)</strong></td>
<td><strong>72% achieved an overall response</strong></td>
<td><strong>ORR: 72% (58–84)</strong></td>
<td><strong>mPFS: 19.2 months (14.4–NR)</strong></td>
<td><strong>3 (Form 3)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Dacomitinib</strong></td>
<td><strong>Advanced</strong></td>
<td><strong>Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial [184, 185]</strong></td>
<td><strong>Gefitinib Control PFS: 9.2 months Control OS: 26.8 months</strong></td>
<td><strong>PFS gain: 5.5 months</strong></td>
<td><strong>OS gain: 7.3 months</strong></td>
<td><strong>OS HR: 0.76 (0.58–0.99)</strong></td>
<td><strong>No improvement in QoL Increased toxicity</strong></td>
</tr>
<tr>
<td><strong>Dabrafenib, a selective inhibitor of mutated forms of BRAF kinase and trametinib, a MEK1/MEK2 inhibitor</strong></td>
<td><strong>Advanced</strong></td>
<td><strong>Dabrafenib plus trametinib in patients with previously untreated BRAF V600E-mutant metastatic NSCLC: an open-label, phase II trial [230]</strong></td>
<td><strong>Cohort study: 36 patients (no control)</strong></td>
<td><strong>Independent review committee-confirmed ORR: 64% (46–79)</strong></td>
<td><strong>mPFS: 10.9 months (7.0–16.6)</strong></td>
<td><strong>Serious adverse events: 57%</strong></td>
<td><strong>2 (Form 3)</strong></td>
</tr>
<tr>
<td>Drug(s)</td>
<td>Advanced</td>
<td>Study Type</td>
<td>Results</td>
<td>Serious Adverse Events</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>----------</td>
<td>------------</td>
<td>---------</td>
<td>-----------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dabrafenib, a selective inhibitor of mutated forms of BRAF kinase and trametinib, a MEK1/MEK2 inhibitor</td>
<td>Advanced</td>
<td>Cohort study: 57 patients (no control)</td>
<td>Independe nt review committee assessed confirmed overall response: 63.2% mPFS: 9.7 months</td>
<td>56%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Entrectinib</td>
<td>Advanced</td>
<td>Single arm</td>
<td>ORR 77% PFS: 19.0 months mDoR 24.6 months</td>
<td>3 (Form 3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Entrectinib</td>
<td>Advanced</td>
<td>Single arm</td>
<td>ORR 57% PFS: 11.2 months mDoR 10.4 months</td>
<td>3 (Form 3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug/Agent</td>
<td>Stage</td>
<td>Distillation</td>
<td>Key Details</td>
<td>Outcomes</td>
<td>Toxicity</td>
<td>Notes</td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>-------</td>
<td>--------------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------</td>
<td>----------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>Erlotinib, an EGFR TKI</td>
<td>Advanced</td>
<td>Erlotinib as maintenance treatment in advanced NSCLC: a multicentre, randomised, placebo-controlled phase III study [127] Phase III NCT00556712</td>
<td>Placebo, as maintenance treatment in advanced NSCLC Control PFS: 11.1 weeks</td>
<td>PFS gain: 1.2 weeks PFS HR: 0.71 (0.62–0.82)</td>
<td>Deteriorated toxicity profile</td>
<td>1 (Form 2b)</td>
<td></td>
</tr>
<tr>
<td>Larotrectinib, a human IgG1 VEGFR2 antagonist</td>
<td>Advanced</td>
<td>Refractory NTRK fusion positive cancers that are advanced, metastatic or not amenable to surgery and have no satisfactory alternative treatments [256] Phase I/II NCT02122913 NCT02637687 NCT02576431</td>
<td>Single arm</td>
<td>RR 75% (independent review) mDoR 9+ months</td>
<td></td>
<td>3 (Form 3)</td>
<td></td>
</tr>
<tr>
<td>Lorlatinib monotherapy treatment of adult patients with ALK-positive advanced NSCLC whose disease has progressed after alectinib or ceritinib as the first ALK TKI therapy, or crizotinib and at least one other ALK TKI</td>
<td>Advanced</td>
<td>ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer [212a] Phase I/II NCT01970865</td>
<td>Cohort study: 139 patients had received ≥ 1 generation ALK TKI (EXP3B to EXPs)</td>
<td>ORR: 40% (95% CI 32%–49%) mDoR: 7.1 months (95% CI 5.6–24.4) mPFS: 6.9 months (95% CI 5.4–8.2)</td>
<td></td>
<td>3 (Form 3)</td>
<td></td>
</tr>
<tr>
<td>Necitumumab, a second-generation</td>
<td>Advanced</td>
<td>Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line therapy in</td>
<td>Gemcitabine and cisplatin as first-line therapy in</td>
<td>OS gain: 1.6 months OS HR: for death 0.84 (0.74–0.96)</td>
<td>Deteriorated toxicity profile</td>
<td>1 (Form 2a)</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>Advanced NSCLC</td>
<td>Phase III</td>
<td>OS Gain (months)</td>
<td>2-Year Survival Gain (%)</td>
<td>OS HR (95% CI)</td>
<td>Toxicity Profile</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>---------------</td>
<td>-----------</td>
<td>------------------</td>
<td>--------------------------</td>
<td>---------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>Recombinant, human IgG1 EGFR antibody in combination with gemcitabine and cisplatin</td>
<td>Nivolumab versus docetaxel in advanced non-squamous NSCLC (Checkmate 057)</td>
<td>NCT01673867</td>
<td>OS: 2.8 months</td>
<td>13%</td>
<td>OS HR: 0.73 (0.60–0.89)</td>
<td>Improved toxicity profile</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nivolumab versus docetaxel in advanced squamous-cell NSCLC (Checkmate 017)</td>
<td>NCT01642004</td>
<td>OS: 3.2 months</td>
<td>15%</td>
<td>OS HR: 0.59 (0.44–0.79)</td>
<td>Improved toxicity profile</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Osimertinib in untreated EGFR-mutated advanced NSCLC (FLAURA)</td>
<td>NCT02296125</td>
<td>PFS: 10.2 Months</td>
<td>Gefitinib or erlotinib in patients with previously untreated, EGFR mutation (exon 19 deletion or L858R)</td>
<td>PFS HR: 0.46 (0.37–0.57)</td>
<td>Improved toxicity profile</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Control OS: 31.8 months</td>
<td></td>
<td>OS HR: 0.80 (0.64–1.00)</td>
<td>QoL similar between arms</td>
<td></td>
</tr>
<tr>
<td>Osimertinib, oral, irreversible EGFR TKI, selective for both <em>EGFR</em> and T790M resistance mutations</td>
<td>Advanced</td>
<td>Osimertinib or platinum-pemetrexed in <em>EGFR T790M</em>-positive lung cancer (AURA3) [195, 195b] Phase III NCT02151981</td>
<td>Pemetrexed plus either carboplatin or cisplatin in patients with <em>T790M</em>-positive, who had disease progression after first-line EGFR TKI therapy Control PFS: 4.4 months</td>
<td>PFS gain: 5.7 months PFS HR: 0.30 (0.23–0.41)</td>
<td>Reduced toxicity Improved patient-reported outcomes 4 (Form 2b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pembrolizumab, an anti-PD-1 monoclonal antibody</td>
<td>Advanced</td>
<td>Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced NSCLC (KEYNOTE-010): a randomised controlled trial [63] Phase III NCT01905657</td>
<td>Docetaxel in patients with previously treated, PD-L1-positive, advanced NSCLC Control OS: 8.5 months</td>
<td>2-year OS rates of 14.5% for docetaxel versus 30.1% for pembrolizumab (2 mg/kg) OS HR: 0.71 (0.58–0.88)</td>
<td>Improved toxicity profile 5 (Form 2a)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pembrolizumab, humanised, IgG4 monoclonal antibody against PD-1</td>
<td>Advanced</td>
<td>Pembrolizumab versus ChT for PDL1-positive NSCLC (KEYNOTE-024) [62, 93, 94a] Phase III NCT02142738</td>
<td>Investigator’s choice of platinum-based ChT in stage IV untreated patients with PD-L1 expression on at least 50% of TCs Control PFS: 6 months OS: 14.2 months</td>
<td>PFS gain: 4.3 months OS gain: 15.8 months PFS HR: 0.50 (0.37–0.68) OS HR: 0.63 (0.47–0.86)</td>
<td>Improved toxicity profile 5 (Form 2a)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pembrolizumab, an anti-PD-1 monoclonal antibody in</td>
<td>Advanced</td>
<td>Pembrolizumab/pemetrexed with platinum ChT in metastatic non-squamous NSCLC without <em>EGFR</em> or <em>ALK</em></td>
<td>Control PFS: 4.9 months Control OS: 11.3 months</td>
<td>PFS gain: 3.9 months PFS HR: 0.52 (0.43–0.64)</td>
<td>Similar toxicity QoL delayed deterioration 4 (Form 2a)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with advanced or mNSCLC who have not previously received systemic therapy for advanced disease</td>
<td>ALK mutations (KEYNOTE-189) [96, 96a, 96b] Phase III NCT02578680</td>
<td>(Crossover allowed) OS gain: above the cut-off of 3 months</td>
<td>OS HR: 0.49 (0.38–0.64)</td>
<td>(exploratory outcome not eligible for upgrade)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pembrolizumab with combination chemotherapy</strong></td>
<td>A study of carboplatin-paclitaxel/nab-paclitaxel chemotherapy with or without pembrolizumab (mk-3475) in adults with first line metastatic squamous non-small cell lung cancer (MK-3475-407/KEYNOTE-407) [99, 99a] Phase III NCT02775435</td>
<td>Placebo plus carboplatin and either paclitaxel or nab-paclitaxel Control PFS: 4.8 months Control OS: 11.3 months</td>
<td>PFS gain: 1.6 months OS gain: 4.6 months</td>
<td>PFS HR: 0.56 (0.45–0.70) OS HR: 0.64 (0.49–0.85)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ramucirumab, a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR2, in combination with docetaxel</strong></td>
<td>Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV NSCLC after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase III trial [157] Phase III NCT01168973</td>
<td>Placebo plus docetaxel in patients with SCC or NSCC who had progressed during or after a first-line platinum-based ChT regimen Control OS: 9.1 months</td>
<td>OS gain: 1.4 months</td>
<td>OS HR: for death 0.86 (0.75–0.98)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ramucirumab, a human IgG1 monoclonal antibody that</strong></td>
<td>A study of ramucirumab (LY3009806) in combination with erlotinib in previously untreated participants with Placebo + erlotinib PFS: 12.4 months</td>
<td>PFS gain: 7 months OS gain: 0.59 (0.46–0.76)</td>
<td>3 (Form 2b)</td>
<td>3 (Form 2b)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>targets the extracellular domain of VEGFR2, in combination with erlotinib</td>
<td>EGFR mutation-positive metastatic NSCLC (RELAY) [193b] Phase III NCT02411448</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*EMA approvals since January 2016.
*ESMO-MCBS version 1.1 [322]. The scores have been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee.
*Calculated estimate of gain based on point estimate HR 0.68.
*EMA approval, October 2015.
*QoL data currently available in abstract form only.
*Two-year survival data currently available in abstract form only.

ALK, anaplastic lymphoma kinase; ChT, chemotherapy; CI, confidence interval; DoR, duration of response; EGFR, endothelial growth factor receptor; EMA, European Medicines Agency; ESMO-MCBS, ESMO-Magnitude of Clinical Benefit Scale; HR, hazard ratio; IgG, immunoglobulin G; mDOR, median duration of response; mPFS, medical progression-free survival; NR, not reached; NSCC, non-squamous cell carcinoma; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PFS, progression-free survival; QoL, quality of life; SCC, squamous cell carcinoma; TC, tumour cell; TKI, tyrosine kinase inhibitor; UL, upper limit; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2; WT, wild-type.
Table 6. Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System\textsuperscript{a})

<table>
<thead>
<tr>
<th>Levels of evidence</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomised trials without heterogeneity</td>
</tr>
<tr>
<td>II</td>
<td>Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity</td>
</tr>
<tr>
<td>III</td>
<td>Prospective cohort studies</td>
</tr>
<tr>
<td>IV</td>
<td>Retrospective cohort studies or case–control studies</td>
</tr>
<tr>
<td>V</td>
<td>Studies without control group, case reports, expert opinions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grades of recommendation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Strong evidence for efficacy with a substantial clinical benefit, strongly recommended</td>
</tr>
<tr>
<td>B</td>
<td>Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended</td>
</tr>
<tr>
<td>C</td>
<td>Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, ...), optional</td>
</tr>
<tr>
<td>D</td>
<td>Moderate evidence against efficacy or for adverse outcome, generally not recommended</td>
</tr>
<tr>
<td>E</td>
<td>Strong evidence against efficacy or for adverse outcome, never recommended</td>
</tr>
</tbody>
</table>

\textsuperscript{a}By permission of the Infectious Diseases Society of America [324].
**Updated version published 15 September 2020 by the ESMO Guidelines Committee**

Figure 1. Treatment algorithm for stage IV SCC.

---

*Molecular testing is not recommended in SCC, except in those rare circumstances when SCC is found in a never-, long-time ex- or light-smoker (< 15 pack-years).

*In absence of contraindications and conditioned by the registration and accessibility of anti-PD-(L)1 combinations with platinum-based ChT, this strategy will be preferred to platinum-based ChT in patients with PS 0-1 and PD-L1 < 50%.

Alternatively, if TMB can accurately be evaluated, and conditioned by the registration and accessibility, nivolumab plus ipilimumab should be preferred to platinum-based standard ChT in patients with NSCLC.

*ESMO-MCBS v1.1 score for new therapy/indication approved by the EMA since 1 January 2016. The score has been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee.

*Not EMA-approved.

*PS > 2 patients were not enrolled in available clinical trials. In the absence of contraindications and conditioned by the registration and accessibility of anti-PD-(L)1 combinations with platinum-based ChT, this strategy might be chosen by analogy to PS 0–1 patients based on investigator opinion. Elderly patients are under-represented in available clinical trials, and frail or comorbid patients ≥ 70 years old shall be evaluated with caution.

ALK, anaplastic lymphoma kinase; BSC, best supportive care; ChT, chemotherapy; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; Mb, megabase; MCBS, ESMO-Magnitude of Clinical Benefit Scale; nab-P, albumin-bound paclitaxel; nab-PC, albumin-bound paclitaxel and carboplatin; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PS, performance status; SCC, squamous cell carcinoma; TMB, tumour mutation burden.
Figure 2. Treatment algorithm for stage IV NSCC, molecular tests negative (ALK/BRAF/EGFR/ROS1).

4In absence of contraindications and conditioned by the registration and accessibility of anti-PD-(L)1 combinations with platinum-based ChT, this strategy will be preferred to platinum-based ChT in patients with PS 0-1 and PD-L1 < 50%. Alternatively, if TMB can accurately be evaluated, and conditioned by the registration and accessibility, nivolumab plus ipilimumab should be preferred to platinum-based standard ChT in patients with NSCLC.

5ESMO-MCBS v1.1 score for new therapy/indication approved by the EMA since 1 January 2016. The score has been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee.

6Not EMA-approved.

7PS > 2 patients were not enrolled in available randomised clinical trials platinum doublet or monotherapy gemcitabine, vinorelbine or docetaxel is sometimes alternatively proposed according to investigators’ assessment [I, B]. Elderly patients are under-represented in available clinical trials, and frail or comorbid patients ≥ 70 years old should be evaluated with caution.

ALK, anaplastic lymphoma kinase; BSC, best supportive care; ChT, chemotherapy; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; IO, immuno-oncology; Mb, megabase; MCBS, ESMO-Magnitude of Clinical Benefit Scale; nab-P, albumin-bound paclitaxel; nab-PC, albumin-bound paclitaxel and carboplatin; NSCC, non-squamous cell carcinoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PS, performance status; TMB, tumour mutation burden.
Figure 3. Treatment algorithm for stage IV NSCC, molecular tests positive (ALK/BRAF/EGFR/ROS1).

- **ESMO-MCBS v1.1** score for new therapy/indication approved by the EMA since 1 January 2016. The score has been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee.
- **Preferred option.**
- **Not EMA-approved.**
- **ESMO-MCBS score for the combination of bevacizumab with gefitinib or erlotinib.**

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; MCBS, ESMO-Magnitude of Clinical Benefit Scale; NSCC, non-squamous cell carcinoma.
Figure 4. Treatment algorithm for stage IV lung carcinoma with EGFR-activating mutation.

*ESMO-MCBS v1.1 score for new therapy/indication approved by the EMA since 1 January 2016. The score has been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee.

bPreferred option [187b].

cESMO-MCBS score for the combination of bevacizumab with gefitinib or erlotinib.

dNot EMA-approved.

cfDNA, cell-free DNA; ChT, chemotherapy; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; MCBS, ESMO-Magnitude of Clinical Benefit Scale; PS, performance status; RT, radiotherapy.
Figure 5. Treatment algorithm for stage IV lung carcinoma with ALK translocation.

**ESMO-MCBS v1.1 score for new therapy/indication approved by the EMA since 1 January 2016. The score has been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee.**

**Preferred option [203a].**

**Not EMA-approved.**

ALK, anaplastic lymphoma kinase; ChT, chemotherapy; EMA, European Medicines Agency; MCBS, ESMO-Magnitude of Clinical Benefit Scale; RT, radiotherapy; TKI, tyrosine kinase inhibitor.
Figure 6. Treatment algorithm for stage IV lung carcinoma with ROS1 translocation.

aESMO-MCBS v1.1 score for new therapy/indication approved by the EMA since 1 January 2016. The score has been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee.
bNot EMA-approved.

ChT, chemotherapy; MCBS, ESMO-Magnitude of Clinical Benefit Scale; TKI, tyrosine kinase inhibitor.
Figure 7. Treatment algorithm for stage IV lung carcinoma with *BRAF* V600 mutation.

### Notes

*ESMO-MCBS v1.1 score for new therapy/indication approved by the EMA since 1 January 2016. The score has been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee.

ChT, chemotherapy; MCBS, ESMO-Magnitude of Clinical Benefit Scale; MEK, mitogen-activated protein kinase kinase.